Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.
A cyclin D subtype which is regulated by GATA4 TRANSCRIPTION FACTOR. Experiments using KNOCKOUT MICE suggest a role for cyclin D2 in granulosa cell proliferation and gonadal development.
A broadly expressed type D cyclin. Experiments using KNOCKOUT MICE suggest a role for cyclin D3 in LYMPHOCYTE development.
A cyclin subtype that has specificity for CDC2 PROTEIN KINASE and CYCLIN-DEPENDENT KINASE 2. It plays a role in progression of the CELL CYCLE through G1/S and G2/M phase transitions.
A cyclin subtype that is specific for CYCLIN-DEPENDENT KINASE 4 and CYCLIN-DEPENDENT KINASE 6. Unlike most cyclins, cyclin D expression is not cyclical, but rather it is expressed in response to proliferative signals. Cyclin D may therefore play a role in cellular responses to mitogenic signals.
A 50-kDa protein that complexes with CYCLIN-DEPENDENT KINASE 2 in the late G1 phase of the cell cycle.
A cyclin subtype that is transported into the CELL NUCLEUS at the end of the G2 PHASE. It stimulates the G2/M phase transition by activating CDC2 PROTEIN KINASE.
A cyclin B subtype that colocalizes with MICROTUBULES during INTERPHASE and is transported into the CELL NUCLEUS at the end of the G2 PHASE.
A cyclin A subtype primarily found in male GERM CELLS. It may play a role in the passage of SPERMATOCYTES into meiosis I.
A large family of regulatory proteins that function as accessory subunits to a variety of CYCLIN-DEPENDENT KINASES. They generally function as ENZYME ACTIVATORS that drive the CELL CYCLE through transitions between phases. A subset of cyclins may also function as transcriptional regulators.
A widely-expressed cyclin A subtype that functions during the G1/S and G2/M transitions of the CELL CYCLE.
Cyclin-dependent kinase 4 is a key regulator of G1 PHASE of the CELL CYCLE. It partners with CYCLIN D to phosphorylate RETINOBLASTOMA PROTEIN. CDK4 activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P16.
Protein kinases that control cell cycle progression in all eukaryotes and require physical association with CYCLINS to achieve full enzymatic activity. Cyclin-dependent kinases are regulated by phosphorylation and dephosphorylation events.
A cyclin G subtype that is constitutively expressed throughout the cell cycle. Cyclin G1 is considered a major transcriptional target of TUMOR SUPPRESSOR PROTEIN P53 and is highly induced in response to DNA damage.
A cyclin subtype that is found associated with CYCLIN-DEPENDENT KINASE 5; cyclin G associated kinase, and PROTEIN PHOSPHATASE 2.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
A key regulator of CELL CYCLE progression. It partners with CYCLIN E to regulate entry into S PHASE and also interacts with CYCLIN A to phosphorylate RETINOBLASTOMA PROTEIN. Its activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P27 and CYCLIN-DEPENDENT KINASE INHIBITOR P21.
The period of the CELL CYCLE preceding DNA REPLICATION in S PHASE. Subphases of G1 include "competence" (to respond to growth factors), G1a (entry into G1), G1b (progression), and G1c (assembly). Progression through the G1 subphases is effected by limiting growth factors, nutrients, or inhibitors.
The B-cell leukemia/lymphoma-1 genes, associated with various neoplasms when overexpressed. Overexpression results from the t(11;14) translocation, which is characteristic of mantle zone-derived B-cell lymphomas. The human c-bcl-1 gene is located at 11q13 on the long arm of chromosome 11.
A cyclin subtype that binds to the CYCLIN-DEPENDENT KINASE 3 and CYCLIN-DEPENDENT KINASE 8. Cyclin C plays a dual role as a transcriptional regulator and a G1 phase CELL CYCLE regulator.
Product of the retinoblastoma tumor suppressor gene. It is a nuclear phosphoprotein hypothesized to normally act as an inhibitor of cell proliferation. Rb protein is absent in retinoblastoma cell lines. It also has been shown to form complexes with the adenovirus E1A protein, the SV40 T antigen, and the human papilloma virus E7 protein.
A family of cell cycle-dependent kinases that are related in structure to CDC28 PROTEIN KINASE; S CEREVISIAE; and the CDC2 PROTEIN KINASE found in mammalian species.
A cyclin B subtype that colocalizes with GOLGI APPARATUS during INTERPHASE and is transported into the CELL NUCLEUS at the end of the G2 PHASE.
A cyclin subtype that is found associated with CYCLIN-DEPENDENT KINASE 9. Unlike traditional cyclins, which regulate the CELL CYCLE, type T cyclins appear to regulate transcription and are components of positive transcriptional elongation factor B.
Proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene (ONCOGENE PROTEINS, FUSION).
A cyclin subtype that is found as a component of a heterotrimeric complex containing cyclin-dependent kinase 7 and CDK-activating kinase assembly factor. The complex plays a role in cellular proliferation by phosphorylating several CYCLIN DEPENDENT KINASES at specific regulatory threonine sites.
Proteins that control the CELL DIVISION CYCLE. This family of proteins includes a wide variety of classes, including CYCLIN-DEPENDENT KINASES, mitogen-activated kinases, CYCLINS, and PHOSPHOPROTEIN PHOSPHATASES as well as their putative substrates such as chromatin-associated proteins, CYTOSKELETAL PROTEINS, and TRANSCRIPTION FACTORS.
Phase of the CELL CYCLE following G1 and preceding G2 when the entire DNA content of the nucleus is replicated. It is achieved by bidirectional replication at multiple sites along each chromosome.
An unusual cyclin subtype that is found highly expressed in terminally differentiated cells. Unlike conventional cyclins increased expression of cyclin G2 is believed to cause a withdrawal of cells from the CELL CYCLE.
Phosphoprotein with protein kinase activity that functions in the G2/M phase transition of the CELL CYCLE. It is the catalytic subunit of the MATURATION-PROMOTING FACTOR and complexes with both CYCLIN A and CYCLIN B in mammalian cells. The maximal activity of cyclin-dependent kinase 1 is achieved when it is fully dephosphorylated.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
A cyclin-dependent kinase inhibitor that mediates TUMOR SUPPRESSOR PROTEIN P53-dependent CELL CYCLE arrest. p21 interacts with a range of CYCLIN-DEPENDENT KINASES and associates with PROLIFERATING CELL NUCLEAR ANTIGEN and CASPASE 3.
The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
A group of enzymes that catalyzes the phosphorylation of serine or threonine residues in proteins, with ATP or other nucleotides as phosphate donors.
A cell line derived from cultured tumor cells.
A cyclin-dependent kinase inhibitor that coordinates the activation of CYCLIN and CYCLIN-DEPENDENT KINASES during the CELL CYCLE. It interacts with active CYCLIN D complexed to CYCLIN-DEPENDENT KINASE 4 in proliferating cells, while in arrested cells it binds and inhibits CYCLIN E complexed to CYCLIN-DEPENDENT KINASE 2.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
A cyclin subtype that is found abundantly in post-mitotic tissues. In contrast to the classical cyclins, its level does not fluctuate during the cell cycle.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A type of CELL NUCLEUS division by means of which the two daughter nuclei normally receive identical complements of the number of CHROMOSOMES of the somatic cells of the species.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A quiescent state of cells during G1 PHASE.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Established cell cultures that have the potential to propagate indefinitely.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
The period of the CELL CYCLE following DNA synthesis (S PHASE) and preceding M PHASE (cell division phase). The CHROMOSOMES are tetraploid in this point.
A family of basic helix-loop-helix transcription factors that control expression of a variety of GENES involved in CELL CYCLE regulation. E2F transcription factors typically form heterodimeric complexes with TRANSCRIPTION FACTOR DP1 or transcription factor DP2, and they have N-terminal DNA binding and dimerization domains. E2F transcription factors can act as mediators of transcriptional repression or transcriptional activation.
A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.
Cyclin-dependent kinase 6 associates with CYCLIN D and phosphorylates RETINOBLASTOMA PROTEIN during G1 PHASE of the CELL CYCLE. It helps regulate the transition to S PHASE and its kinase activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P18.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Cell lines whose original growing procedure consisted being transferred (T) every 3 days and plated at 300,000 cells per plate (J Cell Biol 17:299-313, 1963). Lines have been developed using several different strains of mice. Tissues are usually fibroblasts derived from mouse embryos but other types and sources have been developed as well. The 3T3 lines are valuable in vitro host systems for oncogenic virus transformation studies, since 3T3 cells possess a high sensitivity to CONTACT INHIBITION.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
A glycogen synthase kinase that was originally described as a key enzyme involved in glycogen metabolism. It regulates a diverse array of functions such as CELL DIVISION, microtubule function and APOPTOSIS.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
Tumors or cancer of the human BREAST.
A family of proteins that share the F-BOX MOTIF and are involved in protein-protein interactions. They play an important role in process of protein ubiquition by associating with a variety of substrates and then associating into SCF UBIQUITIN LIGASE complexes. They are held in the ubiquitin-ligase complex via binding to SKP DOMAIN PROTEINS.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Cellular DNA-binding proteins encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.
A continuous cell line of high contact-inhibition established from NIH Swiss mouse embryo cultures. The cells are useful for DNA transfection and transformation studies. (From ATCC [Internet]. Virginia: American Type Culture Collection; c2002 [cited 2002 Sept 26]. Available from http://www.atcc.org/)
An E2F transcription factor that interacts directly with RETINOBLASTOMA PROTEIN and CYCLIN A and activates GENETIC TRANSCRIPTION required for CELL CYCLE entry and DNA synthesis. E2F1 is involved in DNA REPAIR and APOPTOSIS.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A transcription factor that possesses DNA-binding and E2F-binding domains but lacks a transcriptional activation domain. It is a binding partner for E2F TRANSCRIPTION FACTORS and enhances the DNA binding and transactivation function of the DP-E2F complex.
Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
A negative regulator of the CELL CYCLE that undergoes PHOSPHORYLATION by CYCLIN-DEPENDENT KINASES. It contains a conserved pocket region that binds E2F4 TRANSCRIPTION FACTOR and interacts with viral ONCOPROTEINS such as POLYOMAVIRUS TUMOR ANTIGENS; ADENOVIRUS E1A PROTEINS; and PAPILLOMAVIRUS E7 PROTEINS.
A subclass of dual specificity phosphatases that play a role in the progression of the CELL CYCLE. They dephosphorylate and activate CYCLIN-DEPENDENT KINASES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A ubiquitously expressed regulatory protein that contains a retinoblastoma protein binding domain and an AT-rich interactive domain. The protein may play a role in recruiting HISTONE DEACETYLASES to the site of RETINOBLASTOMA PROTEIN-containing transcriptional repressor complexes.
A large multisubunit complex that plays an important role in the degradation of most of the cytosolic and nuclear proteins in eukaryotic cells. It contains a 700-kDa catalytic sub-complex and two 700-kDa regulatory sub-complexes. The complex digests ubiquitinated proteins and protein activated via ornithine decarboxylase antizyme.
A family of structurally-related proteins that were originally identified by their ability to complex with cyclin proteins (CYCLINS). They share a common domain that binds specifically to F-BOX MOTIFS. They take part in SKP CULLIN F-BOX PROTEIN LIGASES, where they can bind to a variety of F-BOX PROTEINS.
The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for VIRUS CULTIVATION and antitumor drug screening assays.
Regulatory signaling systems that control the progression through the CELL CYCLE. They ensure that the cell has completed, in the correct order and without mistakes, all the processes required to replicate the GENOME and CYTOPLASM, and divide them equally between two daughter cells. If cells sense they have not completed these processes or that the environment does not have the nutrients and growth hormones in place to proceed, then the cells are restrained (or "arrested") until the processes are completed and growth conditions are suitable.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins.
Elements of limited time intervals, contributing to particular results or situations.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies.
A protein-serine-threonine kinase that is activated by PHOSPHORYLATION in response to GROWTH FACTORS or INSULIN. It plays a major role in cell metabolism, growth, and survival as a core component of SIGNAL TRANSDUCTION. Three isoforms have been described in mammalian cells.
Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate.
Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques.
A family of enzymes that catalyze the conversion of ATP and a protein to ADP and a phosphoprotein.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A gene silencing phenomenon whereby specific dsRNAs (RNA, DOUBLE-STRANDED) trigger the degradation of homologous mRNA (RNA, MESSENGER). The specific dsRNAs are processed into SMALL INTERFERING RNA (siRNA) which serves as a guide for cleavage of the homologous mRNA in the RNA-INDUCED SILENCING COMPLEX. DNA METHYLATION may also be triggered during this process.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Processes that stimulate the GENETIC TRANSCRIPTION of a gene or set of genes.
High molecular weight proteins found in the MICROTUBULES of the cytoskeletal system. Under certain conditions they are required for TUBULIN assembly into the microtubules and stabilize the assembled microtubules.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
MAMMARY GLANDS in the non-human MAMMALS.
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
An aspect of protein kinase (EC 2.7.1.37) in which serine residues in protamines and histones are phosphorylated in the presence of ATP.
Transport proteins that carry specific substances in the blood or across cell membranes.
A group of cell cycle proteins that negatively regulate the activity of CYCLIN/CYCLIN-DEPENDENT KINASE complexes. They inhibit CELL CYCLE progression and help control CELL PROLIFERATION following GENOTOXIC STRESS as well as during CELL DIFFERENTIATION.
An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Regulatory signaling systems that control the progression of the CELL CYCLE through the G1 PHASE and allow transition to S PHASE when the cells are ready to undergo DNA REPLICATION. DNA DAMAGE, or the deficiencies in specific cellular components or nutrients may cause the cells to halt before progressing through G1 phase.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell.
Protein kinase that drives both the mitotic and meiotic cycles in all eukaryotic organisms. In meiosis it induces immature oocytes to undergo meiotic maturation. In mitosis it has a role in the G2/M phase transition. Once activated by CYCLINS; MPF directly phosphorylates some of the proteins involved in nuclear envelope breakdown, chromosome condensation, spindle assembly, and the degradation of cyclins. The catalytic subunit of MPF is PROTEIN P34CDC2.
A superfamily of PROTEIN-SERINE-THREONINE KINASES that are activated by diverse stimuli via protein kinase cascades. They are the final components of the cascades, activated by phosphorylation by MITOGEN-ACTIVATED PROTEIN KINASE KINASES, which in turn are activated by mitogen-activated protein kinase kinase kinases (MAP KINASE KINASE KINASES).
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Enzymes that oxidize certain LUMINESCENT AGENTS to emit light (PHYSICAL LUMINESCENCE). The luciferases from different organisms have evolved differently so have different structures and substrates.
A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine).
Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8.
The aggregation of soluble ANTIGENS with ANTIBODIES, alone or with antibody binding factors such as ANTI-ANTIBODIES or STAPHYLOCOCCAL PROTEIN A, into complexes large enough to fall out of solution.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Processes required for CELL ENLARGEMENT and CELL PROLIFERATION.
Gated transport mechanisms by which proteins or RNA are moved across the NUCLEAR MEMBRANE.
A multifunctional CDC2 kinase-related kinase that plays roles in transcriptional elongation, CELL DIFFERENTIATION, and APOPTOSIS. It is found associated with CYCLIN T and is a component of POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B.
A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.
A family of proteins that are structurally-related to Ubiquitin. Ubiquitins and ubiquitin-like proteins participate in diverse cellular functions, such as protein degradation and HEAT-SHOCK RESPONSE, by conjugation to other proteins.
The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990)
Echinoderms having bodies of usually five radially disposed arms coalescing at the center.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
The process by which a DNA molecule is duplicated.
An E2F transcription factor that represses GENETIC TRANSCRIPTION required for CELL CYCLE entry and DNA synthesis. E2F4 recruits chromatin remodeling factors indirectly to target gene PROMOTER REGIONS through RETINOBLASTOMA LIKE PROTEIN P130 and RETINOBLASTOMA LIKE PROTEIN P107.
Complexes of enzymes that catalyze the covalent attachment of UBIQUITIN to other proteins by forming a peptide bond between the C-terminal GLYCINE of UBIQUITIN and the alpha-amino groups of LYSINE residues in the protein. The complexes play an important role in mediating the selective-degradation of short-lived and abnormal proteins. The complex of enzymes can be broken down into three components that involve activation of ubiquitin (UBIQUITIN-ACTIVATING ENZYMES), conjugation of ubiquitin to the ligase complex (UBIQUITIN-CONJUGATING ENZYMES), and ligation of ubiquitin to the substrate protein (UBIQUITIN-PROTEIN LIGASES).
Detection of RNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-6 family members. STAT3 is constitutively activated in a variety of TUMORS and is a major downstream transducer for the CYTOKINE RECEPTOR GP130.

Coupling of the cell cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with cdk4. (1/3253)

Proliferating myoblasts express the muscle determination factor, MyoD, throughout the cell cycle in the absence of differentiation. Here we show that a mitogen-sensitive mechanism, involving the direct interaction between MyoD and cdk4, restricts myoblast differentiation to cells that have entered into the G0 phase of the cell cycle under mitogen withdrawal. Interaction between MyoD and cdk4 disrupts MyoD DNA-binding, muscle-specific gene activation and myogenic conversion of 10T1/2 cells independently of cyclin D1 and the CAK activation of cdk4. Forced induction of cyclin D1 in myotubes results in the cytoplasmic to nuclear translocation of cdk4. The specific MyoD-cdk4 interaction in dividing myoblasts, coupled with the cyclin D1-dependent nuclear targeting of cdk4, suggests a mitogen-sensitive mechanism whereby cyclin D1 can regulate MyoD function and the onset of myogenesis by controlling the cellular location of cdk4 rather than the phosphorylation status of MyoD.  (+info)

Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. (2/3253)

The irreversible G1 arrest in senescent human diploid fibroblasts is probably caused by inactivation of the G1 cyclin-cyclin-dependent kinase (Cdk) complexes responsible for phosphorylation of the retinoblastoma protein (pRb). We show that the Cdk inhibitor p21(Sdi1,Cip1,Waf1), which accumulates progressively in aging cells, binds to and inactivates all cyclin E-Cdk2 complexes in senescent cells, whereas in young cells only p21-free Cdk2 complexes are active. Furthermore, the senescent-cell-cycle arrest occurs prior to the accumulation of the Cdk4-Cdk6 inhibitor p16(Ink4a), suggesting that p21 may be sufficient for this event. Accordingly, cyclin D1-associated phosphorylation of pRb at Ser-780 is lacking even in newly senescent fibroblasts that have a low amount of p16. Instead, the cyclin D1-Cdk4 and cyclin D1-Cdk6 complexes in these cells are associated with an increased amount of p21, suggesting that p21 may be responsible for inactivation of both cyclin E- and cyclin D1-associated kinase activity at the early stage of senescence. Moreover, even in the late stage of senescence when p16 is high, cyclin D1-Cdk4 complexes are persistent, albeit reduced by +info)

Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. (3/3253)

The response of the uterine epithelium to female sex steroid hormones provides an excellent model to study cell proliferation in vivo since both stimulation and inhibition of cell proliferation can be studied. Thus, when administered to ovariectomized adult mice 17beta-estradiol (E2) stimulates a synchronized wave of DNA synthesis and cell division in the epithelial cells, while pretreatment with progesterone (P4) completely inhibits this E2-induced cell proliferation. Using a simple method to isolate the uterine epithelium with high purity, we have shown that E2 treatment induces a relocalization of cyclin D1 and, to a lesser extent, cdk4 from the cytoplasm into the nucleus and results in the orderly activation of cyclin E- and cyclin A-cdk2 kinases and hyperphosphorylation of pRb and p107. P4 pretreatment did not alter overall levels of cyclin D1, cdk4, or cdk6 nor their associated kinase activities but instead inhibited the E2-induced nuclear localization of cyclin D1 to below the control level and, to a lesser extent, nuclear cdk4 levels, with a consequent inhibition of pRb and p107 phosphorylation. In addition, it abrogated E2-induced cyclin E-cdk2 activation by dephosphorylation of cdk2, followed by inhibition of cyclin A expression and consequently of cyclin A-cdk2 kinase activity and further inhibition of phosphorylation of pRb and p107. P4 is used therapeutically to oppose the effect of E2 during hormone replacement therapy and in the treatment of uterine adenocarcinoma. This study showing a novel mechanism of cell cycle inhibition by P4 may provide the basis for the development of new antiestrogens.  (+info)

Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. (4/3253)

Oncogenes are often dysregulated in B cell tumors as a result of a reciprocal translocation involving an immunoglobulin locus. The translocations are caused by errors in two developmentally regulated DNA recombination processes: V(D)J and IgH switch recombination. Both processes share the property of joining discontinuous sequences from one chromosome and releasing intervening sequences as circles that are lost from progeny cells. Here we show that these intervening sequences may instead insert in the genome and that during productive IgH mu-epsilon switch recombination in U266 myeloma tumor cells, a portion of the excised IgH switch intervening sequences containing the 3' alpha-1 enhancer has inserted on chromosome 11q13, resulting in overexpression of the adjacent cyclin D1 oncogene.  (+info)

Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. (5/3253)

Fibronectin (FN) is comprised of multiple isoforms arising from alternative splicing of a single gene transcript. One of the alternatively spliced segments, EDA, is expressed prominently in embryonic development, malignant transformation, and wound healing. We showed previously that EDA+ FN was more potent than EDA- FN in promoting cell spreading and cell migration because of its enhanced binding affinity to integrin alpha5beta1 (Manabe, R., Oh-e, N., Maeda, T., Fukuda, T., and Sekiguchi, K. (1997) J. Cell Biol. 139, 295-307). In this study, we compared the cell cycle progression and its associated signal transduction events induced by FN isoforms with or without the EDA segment to examine whether the EDA segment modulates the cell proliferative potential of FN. We found that EDA+ FN was more potent than EDA- FN in inducing G1-S phase transition. Inclusion of the EDA segment potentiated the ability of FN to induce expression of cyclin D1, hyperphosphorylation of pRb, and activation of mitogen-activated protein kinase extracellular signal regulated kinase 2 (ERK2). EDA+ FN was also more potent than EDA- FN in promoting FN-mediated tyrosine phosphorylation of p130(Cas), but not focal adhesion kinase, which occurred in parallel with the activation of ERK2, suggesting that p130(Cas) may be involved in activation of ERK2. These results indicated that alternative splicing at the EDA region is a novel mechanism that promotes FN-induced cell cycle progression through up-regulation of integrin-mediated mitogenic signal transduction.  (+info)

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. (6/3253)

Prostate cancer development and progression is driven by the accumulation of genetic changes, the nature of which remains incompletely understood To facilitate high-throughput analysis of molecular events taking place in primary, recurrent, and metastat prostate cancer, we constructed a tissue microarray containing small 0.6-mm cylindrical samples acquired from 371 formalin-fixed blocks, including benign prostatic hyperplasia (n = 32) and primary tumors (n = 223), as well as both locally recurrent tumors (n = 54) and metastases (n = 62) from patients with hormone-refractory disease. Fluorescence in situ hybridization (FISH) was applied to the analysis of consecutive tissue microarray sections with probes for five different genes. High-level (> or =3X) amplifications were very rare (<2%) in primary prostate cancers However, in metastases from patients with hormone-refractory disease, amplification of the androgen receptor gene was seen in 22%, MYC in 11%, and Cyclin-D1 in 5% of the cases. In specimens from locally recurrent tumors, the corresponding percentages were 23, 4, and 8%. ERBB2 and NMYC amplifications were never detected at any stage of prostate cancer progression. In conclusion, FISH to tissue microarray sections enables high-throughput analysis of genetic alterations contributing to cancer development and progression. Our results implicate a role for amplification of androgen receptor in hormonal therapy failure and that of MYC in the metastatic progression of human prostate cancer.  (+info)

Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. (7/3253)

Lung cancer results from a stepwise accumulation of genetic and molecular abnormalities with unknown temporal relationships to precursor bronchial lesions. In a search for biomarkers of malignant progression, we analyzed the expression of the tumor suppressor gene Rb and of the proteins regulating its phosphorylation and function in G1 arrest, p16INK4A and cyclin D1, in preinvasive bronchial lesions accompanying cancer in 75 patients, in comparison with similar lesions in 22 patients with no cancer history. Rb was constantly expressed in preinvasive lesions, including carcinoma in situ (CIS). In contrast, p16 expression was lost in moderate dysplasia (12%) and in CIS (30%) in patients with lung cancer. p16 loss occurred exclusively in patients who displayed loss of p16 expression in their related invasive carcinoma. Loss of p16 expression was not seen in nine patients with dysplasia but no cancer progression. Cyclin D1 overexpression was seen in hyperplasia and metaplasia (6%), mild dysplasia (17%), moderate dysplasia (46%), and CIS (38%) in patients with cancer but was lost in 5% of the patients during the process of invasion; it was also observed in patients with no cancer progression (14%). Our results indicate that Rb protein function can be invalidated before invasion through alteration of the Rb phosphorylation pathway, by p16 inhibition, and/or by cyclin D1 overexpression and suggest a role for p16 and cyclin D1 deregulation in progression of preinvasive bronchial lesions to invasive carcinoma.  (+info)

Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. (8/3253)

BACKGROUND: Retinoids (derivatives of vitamin A) are reported to reduce the occurrence of some second primary cancers, including aerodigestive tract tumors. In contrast, beta-carotene does not reduce the occurrence of primary aerodigestive tract cancers. Mechanisms explaining these effective retinoid and ineffective carotenoid chemoprevention results are poorly defined. Recently, the all-trans-retinoic acid (RA)-induced proteolysis of cyclin D1 that leads to the arrest of cells in G1 phase of the cell cycle was described in human bronchial epithelial cells and is a promising candidate for such a mechanism. In this study, we have investigated this proteolysis as a common signal used by carotenoids or receptor-selective and receptor-nonselective retinoids. METHODS: We treated cultured normal human bronchial epithelial cells, immortalized human bronchial epithelial cells (BEAS-2B), and transformed human bronchial epithelial cells (BEAS-2BNNK) with receptor-selective or receptor-nonselective retinoids or with carotenoids and studied the effects on cell proliferation by means of tritiated thymidine incorporation and on cyclin D1 expression by means of immunoblot analysis. We also examined whether calpain inhibitor I, an inhibitor of the 26S proteasome degradation pathway, affected the decline (i.e., proteolysis) of cyclin D1. RESULTS: Receptor-nonselective retinoids were superior to the carotenoids studied in mediating the decline in cyclin D1 expression and in suppressing the growth of bronchial epithelial cells. Retinoids that activated retinoic acid receptor beta or retinoid X receptor pathways preferentially led to a decrease in the amount of cyclin D1 protein and a corresponding decline in growth. The retinoid-mediated degradation of cyclin D1 was blocked by cotreatment with calpain inhibitor I. CONCLUSIONS: Retinoid-dependent cyclin D1 proteolysis is a common chemoprevention signal in normal and neoplastic human bronchial epithelial cells. In contrast, carotenoids did not affect cyclin D1 expression. Thus, the degradation of cyclin D1 is a candidate intermediate marker for effective retinoid-mediated cancer chemoprevention in the aerodigestive tract.  (+info)

Cyclin D1 is a protein that plays a critical role in regulating the progression of the cell cycle from the G1 phase to the S phase. It is encoded by the CCND1 gene and is expressed in a variety of tissues, including epithelial cells, fibroblasts, and leukocytes. In the cell cycle, cyclin D1 binds to and activates cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6. This complex then phosphorylates retinoblastoma protein (Rb), which releases the transcription factor E2F from its inhibition. E2F then activates the transcription of genes required for DNA synthesis and cell proliferation. Abnormal expression or activity of cyclin D1 has been implicated in the development of various types of cancer, including breast, prostate, and lung cancer. Overexpression of cyclin D1 can lead to uncontrolled cell proliferation and the formation of tumors. Conversely, loss of cyclin D1 function has been associated with cell cycle arrest and the development of cancer.

Cyclin D2 is a protein that plays a role in regulating the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Cyclin D2 is expressed at high levels in cells that are actively dividing, and it helps to promote the progression of the cell cycle from the G1 phase (the first phase of interphase) to the S phase (the second phase of interphase), where DNA replication occurs. In the medical field, cyclin D2 is often studied in the context of cancer. Abnormal expression or activity of cyclin D2 has been linked to the development and progression of various types of cancer, including breast cancer, ovarian cancer, and prostate cancer. In these cases, cyclin D2 may contribute to uncontrolled cell growth and division, leading to the formation of tumors. Cyclin D2 is also being studied as a potential therapeutic target in cancer treatment. Researchers are exploring the use of drugs that inhibit the activity of cyclin D2 as a way to slow or stop the growth of cancer cells.

Cyclin D3 is a protein that plays a role in regulating the progression of the cell cycle, which is the process by which cells grow and divide. It is a type of cyclin, which are proteins that are involved in regulating the cell cycle by interacting with cyclin-dependent kinases (CDKs). Cyclin D3 is expressed primarily in cells that are actively dividing, such as those in the skin, bone marrow, and breast. It helps to promote the progression of the cell cycle from the G1 phase (the first phase of the cell cycle) to the S phase (the second phase), where DNA replication occurs. Abnormal expression of cyclin D3 has been linked to the development of certain types of cancer, including breast, prostate, and colon cancer.

Cyclin A is a protein that plays a crucial role in regulating the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Cyclin A is synthesized in the S phase of the cell cycle, when the cell is preparing to divide, and is degraded as the cell enters the G2 phase, before it actually divides. Cyclin A forms a complex with the cyclin-dependent kinase (CDK) 2, which is a key regulator of the cell cycle. This complex phosphorylates a variety of target proteins, including the retinoblastoma protein (Rb), which is a tumor suppressor that prevents cells from dividing unless they have completed the necessary DNA replication and repair processes. When Cyclin A and CDK2 are activated, they promote the progression of the cell cycle from the S phase to the G2 phase, and ultimately to mitosis, the process by which the cell divides into two daughter cells. Dysregulation of Cyclin A expression or activity has been implicated in a variety of diseases, including cancer, where it can contribute to uncontrolled cell proliferation and tumor growth.

Cyclin D is a protein that plays a critical role in regulating the progression of the cell cycle, which is the process by which cells divide and replicate. Cyclin D is synthesized in response to growth signals and helps to promote the transition of cells from the G1 phase (interphase) to the S phase (synthesis phase) of the cell cycle. During the S phase, the cell replicates its DNA in preparation for cell division. Cyclin D is often overexpressed in cancer cells, leading to uncontrolled cell proliferation and the development of tumors. In addition, mutations in the genes that encode cyclin D or its regulatory proteins can also contribute to the development of cancer. Cyclin D is a target for several cancer therapies, including targeted therapies that block the activity of cyclin D or its downstream signaling pathways. Understanding the role of cyclin D in the cell cycle and its role in cancer is an active area of research in the medical field.

Cyclin E is a protein that plays a crucial role in regulating the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Cyclin E is synthesized in the late G1 phase of the cell cycle and is degraded as the cell enters the S phase, where DNA replication occurs. Cyclin E functions by binding to and activating the cyclin-dependent kinase (CDK) 2, which is a key regulator of the G1/S transition. The cyclin E-CDK2 complex phosphorylates several target proteins, including the retinoblastoma protein (Rb), which is a tumor suppressor that inhibits cell cycle progression. When cyclin E-CDK2 is activated, it phosphorylates Rb, releasing it from its inhibitory complex and allowing the cell to progress into the S phase. Abnormal expression or activity of cyclin E has been implicated in the development of several types of cancer, including breast, ovarian, and cervical cancer. In these cancers, high levels of cyclin E can lead to uncontrolled cell proliferation and the formation of tumors. Therefore, cyclin E is an important target for cancer therapy, and several drugs that target cyclin E or its downstream targets are currently being developed for the treatment of cancer.

Cyclin B is a protein that plays a crucial role in regulating the progression of the cell cycle, particularly during the M phase (mitosis). It is synthesized and degraded in a tightly regulated manner, with its levels increasing just before the onset of mitosis and decreasing afterwards. Cyclin B forms a complex with the cyclin-dependent kinase (CDK) 1, which is also known as Cdk1. This complex is responsible for phosphorylating various target proteins, including the nuclear envelope, kinetochores, and microtubules, which are essential for the proper progression of mitosis. Disruptions in the regulation of cyclin B and CDK1 activity can lead to various diseases, including cancer. For example, overexpression of cyclin B or mutations in CDK1 can result in uncontrolled cell proliferation and the development of tumors. Conversely, loss of cyclin B function can lead to cell cycle arrest and genomic instability, which can also contribute to cancer development.

Cyclin B1 is a protein that plays a crucial role in regulating the progression of the cell cycle, particularly during the M phase (mitosis). It is synthesized and degraded in a tightly regulated manner, with its levels increasing just before the onset of mitosis and decreasing afterwards. Cyclin B1 forms a complex with the cyclin-dependent kinase (CDK) 1, which is a key regulator of cell division. This complex phosphorylates various target proteins, including the nuclear envelope, microtubules, and other cell cycle regulators, to promote the progression of mitosis. Mutations in the gene encoding cyclin B1 have been implicated in several human diseases, including cancer. In particular, overexpression of cyclin B1 has been observed in many types of cancer, and it has been proposed that this contributes to uncontrolled cell proliferation and tumor growth.

Cyclin A1 is a protein that plays a role in regulating the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Cyclin A1 is synthesized in response to cell growth signals and helps to coordinate the progression of the cell cycle through the different stages, including DNA replication and cell division. It is expressed primarily in cells that are actively dividing, such as those in the liver, kidney, and testes. In the medical field, cyclin A1 is often studied in the context of cancer, as its overexpression has been linked to the development and progression of certain types of tumors.

Cyclins are a family of proteins that play a critical role in regulating the progression of the cell cycle in eukaryotic cells. They are synthesized and degraded in a cyclic manner, hence their name, and their levels fluctuate throughout the cell cycle. Cyclins interact with cyclin-dependent kinases (CDKs) to form cyclin-CDK complexes, which are responsible for phosphorylating target proteins and regulating cell cycle progression. Different cyclins are associated with different stages of the cell cycle, and their activity is tightly regulated by various mechanisms, including post-translational modifications and proteolysis. Dysregulation of cyclin expression or activity has been implicated in a variety of diseases, including cancer, where it is often associated with uncontrolled cell proliferation and tumor growth. Therefore, understanding the mechanisms that regulate cyclin expression and activity is important for developing new therapeutic strategies for cancer and other diseases.

Cyclin A2 is a protein that plays a role in regulating the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Cyclin A2 is synthesized in response to cell growth signals and helps to coordinate the progression of the cell cycle through its interaction with cyclin-dependent kinases (CDKs). Specifically, Cyclin A2 forms a complex with CDK2, which is a key regulator of the G1/S transition, the point at which cells move from the G1 phase (resting phase) to the S phase (synthesis phase) of the cell cycle. This complex helps to phosphorylate and activate other proteins involved in the cell cycle, allowing cells to progress through the G1/S transition and enter the S phase. Cyclin A2 is also involved in the regulation of DNA replication and mitosis, the process by which cells divide into two daughter cells.

Cyclin-dependent kinase 4 (CDK4) is a protein that plays a critical role in regulating the cell cycle, which is the process by which cells divide and replicate. CDK4 is a member of the cyclin-dependent kinase (CDK) family of proteins, which are involved in regulating various cellular processes, including cell division, DNA replication, and transcription. CDK4 is activated by binding to cyclin D, a regulatory protein that is produced in response to growth signals. Once activated, CDK4 phosphorylates a number of target proteins, including the retinoblastoma protein (Rb), which is a key regulator of the cell cycle. Phosphorylation of Rb leads to its inactivation, allowing the cell to progress through the cell cycle and divide. Abnormal regulation of CDK4 activity has been implicated in a number of diseases, including cancer. For example, mutations in the CDK4 gene or overexpression of CDK4 have been found in various types of cancer, including breast, prostate, and lung cancer. In these cases, CDK4 may contribute to uncontrolled cell division and the development of tumors. In the medical field, CDK4 inhibitors are being developed as potential treatments for cancer. These drugs work by blocking the activity of CDK4, thereby inhibiting the growth and proliferation of cancer cells. Some CDK4 inhibitors have already been approved for use in certain types of cancer, and others are currently being tested in clinical trials.

Cyclin-dependent kinases (CDKs) are a family of protein kinases that play a critical role in regulating cell cycle progression in eukaryotic cells. They are activated by binding to specific regulatory proteins called cyclins, which are synthesized and degraded in a cyclic manner throughout the cell cycle. CDKs phosphorylate target proteins, including other kinases and transcription factors, to promote or inhibit cell cycle progression at specific points. Dysregulation of CDK activity has been implicated in a variety of diseases, including cancer, and is a target for therapeutic intervention.

Cyclin G1 is a protein that plays a role in regulating the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Cyclin G1 is expressed at low levels in most cells, but its levels increase during the G1 phase of the cell cycle, which is the phase when the cell prepares for DNA replication. Cyclin G1 works by binding to and activating an enzyme called cyclin-dependent kinase 4 (CDK4), which in turn phosphorylates and inactivates the retinoblastoma protein (Rb). This inactivation of Rb allows the cell to progress through the G1 phase and enter the S phase, where DNA replication occurs. Dysregulation of cyclin G1 expression or activity has been implicated in the development of various types of cancer.

Cyclin G is a protein that plays a role in regulating the cell cycle, which is the process by which cells divide and grow. It is a type of cyclin, which are proteins that are involved in regulating the progression of the cell cycle through different phases. Cyclin G is expressed at low levels in most cells, but its levels increase during certain stages of the cell cycle, particularly during the G1 phase, which is the first phase of the cell cycle. Cyclin G is thought to help regulate the progression of the cell cycle by interacting with and activating cyclin-dependent kinases (CDKs), which are enzymes that control the progression of the cell cycle. Dysregulation of cyclin G expression or function has been implicated in the development of various types of cancer.

Cyclin-dependent kinase 2 (CDK2) is an enzyme that plays a critical role in cell cycle regulation. It is a member of the cyclin-dependent kinase (CDK) family of proteins, which are involved in the control of cell division and progression through the cell cycle. CDK2 is activated by binding to cyclin A, a regulatory protein that is expressed during the S phase of the cell cycle. Once activated, CDK2 phosphorylates a variety of target proteins, including the retinoblastoma protein (Rb), which is a key regulator of the cell cycle. Phosphorylation of Rb leads to its inactivation and the release of the transcription factor E2F, which promotes the transcription of genes required for DNA replication and cell division. CDK2 is also involved in the regulation of other cellular processes, including DNA repair, apoptosis, and differentiation. Dysregulation of CDK2 activity has been implicated in a number of diseases, including cancer, where it is often overexpressed or mutated. As such, CDK2 is a target for the development of new cancer therapies.

Cyclin C is a protein that plays a role in regulating the cell cycle, which is the process by which cells divide and grow. It is a member of the cyclin family of proteins, which are involved in regulating the progression of the cell cycle through different phases. Cyclin C is primarily expressed in the brain and is involved in the regulation of neural development and function. It has also been implicated in the development of certain types of cancer, including breast cancer and glioblastoma. In the medical field, cyclin C is studied as a potential target for the development of new treatments for these and other diseases.

Retinoblastoma protein (pRb) is a tumor suppressor protein that plays a critical role in regulating cell cycle progression and preventing the development of cancer. It is encoded by the RB1 gene, which is located on chromosome 13. In normal cells, pRb functions as a regulator of the cell cycle by binding to and inhibiting the activity of the E2F family of transcription factors. When cells are damaged or under stress, pRb is phosphorylated, which leads to its release from E2F and allows the cell to proceed through the cell cycle and divide. However, in cells with a mutated RB1 gene, pRb is unable to function properly, leading to uncontrolled cell division and the formation of tumors. Retinoblastoma is a type of eye cancer that occurs almost exclusively in children and is caused by mutations in the RB1 gene. Other types of cancer, such as osteosarcoma and small cell lung cancer, can also be associated with mutations in the RB1 gene.

CDC2-CDC28 kinases are a family of protein kinases that play a critical role in regulating cell cycle progression in eukaryotic cells. These kinases are named after the two genes that were originally identified in yeast, CDC2 and CDC28. CDC2-CDC28 kinases are involved in several key events during the cell cycle, including the initiation of DNA replication, the progression through the G1, S, G2, and M phases, and the regulation of mitosis. They are also involved in the regulation of cell growth, differentiation, and apoptosis. Inactivation of CDC2-CDC28 kinases can lead to cell cycle arrest, which can have both positive and negative effects on cell function. For example, cell cycle arrest can prevent the proliferation of cancer cells, but it can also lead to cell death in cells that are unable to repair damaged DNA. In the medical field, CDC2-CDC28 kinases are of interest as potential therapeutic targets for the treatment of various diseases, including cancer, as well as for the development of new drugs to regulate cell cycle progression and cell growth.

Cyclin B2 is a protein that plays a crucial role in regulating the progression of the cell cycle, particularly during the G2/M phase. It is a member of the cyclin family of proteins, which are involved in regulating the cell cycle by interacting with cyclin-dependent kinases (CDKs). Cyclin B2 is synthesized and degraded in a tightly regulated manner during the cell cycle. It is synthesized during the G2 phase and accumulates in the cell until the onset of mitosis, at which point it binds to and activates CDK1, forming the cyclin B1/CDK1 complex. This complex is essential for the initiation of mitosis and the proper progression of the cell through the M phase. Disruptions in the regulation of cyclin B2 expression or activity have been implicated in a variety of diseases, including cancer. For example, overexpression of cyclin B2 has been observed in several types of cancer, and it has been suggested that this may contribute to the uncontrolled proliferation of cancer cells. Conversely, loss of cyclin B2 function has been associated with defects in cell cycle progression and may contribute to the development of certain types of cancer.

Cyclin T is a protein that plays a role in regulating the progression of the cell cycle. It is a subunit of the cyclin-dependent kinase 9 (CDK9) complex, which is involved in the transcription of RNA. Cyclin T is essential for the activation of the transcription factor elongation factor 2 (EF2), which is responsible for the synthesis of proteins. In the context of the medical field, cyclin T has been implicated in the regulation of various cellular processes, including cell proliferation, differentiation, and apoptosis. Dysregulation of cyclin T has been associated with several diseases, including cancer, viral infections, and neurological disorders.

Oncogenes are genes that have the potential to cause cancer when they are mutated or expressed at high levels. Oncogenes are also known as proto-oncogenes, and they are involved in regulating cell growth and division. When oncogenes are mutated or expressed at high levels, they can cause uncontrolled cell growth and division, leading to the development of cancer. Oncogene proteins are the proteins that are produced by oncogenes. These proteins can play a variety of roles in the development and progression of cancer, including promoting cell growth and division, inhibiting cell death, and contributing to the formation of tumors.

Cyclin H is a protein that plays a role in the regulation of cell division. It is a component of the cyclin-dependent kinase (CDK) complex, which is responsible for phosphorylating target proteins and regulating the progression of the cell cycle. Cyclin H is involved in the transition from the G1 phase to the S phase of the cell cycle, where DNA replication occurs. It is also involved in the regulation of DNA repair and the maintenance of genomic stability. Mutations in the gene encoding cyclin H have been associated with an increased risk of certain types of cancer, including colorectal and ovarian cancer.

Cell cycle proteins are a group of proteins that play a crucial role in regulating the progression of the cell cycle. The cell cycle is a series of events that a cell goes through in order to divide and produce two daughter cells. It consists of four main phases: G1 (Gap 1), S (Synthesis), G2 (Gap 2), and M (Mitosis). Cell cycle proteins are involved in regulating the progression of each phase of the cell cycle, ensuring that the cell divides correctly and that the daughter cells have the correct number of chromosomes. Some of the key cell cycle proteins include cyclins, cyclin-dependent kinases (CDKs), and checkpoint proteins. Cyclins are proteins that are synthesized and degraded in a cyclic manner throughout the cell cycle. They bind to CDKs, which are enzymes that regulate cell cycle progression by phosphorylating target proteins. The activity of CDKs is tightly regulated by cyclins, ensuring that the cell cycle progresses in a controlled manner. Checkpoint proteins are proteins that monitor the cell cycle and ensure that the cell does not proceed to the next phase until all the necessary conditions are met. If any errors are detected, checkpoint proteins can halt the cell cycle and activate repair mechanisms to correct the problem. Overall, cell cycle proteins play a critical role in maintaining the integrity of the cell cycle and ensuring that cells divide correctly. Disruptions in the regulation of cell cycle proteins can lead to a variety of diseases, including cancer.

Cyclin G2 is a protein that plays a role in regulating the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Cyclin G2 is involved in the transition from the G1 phase (the first stage of the cell cycle) to the S phase (the stage where DNA replication occurs). It is also involved in the regulation of the G2/M transition, which is the stage where the cell prepares to divide. In the medical field, Cyclin G2 has been implicated in the development of certain types of cancer, including breast cancer and ovarian cancer. It is also being studied as a potential target for cancer therapy.

CDC2 Protein Kinase is a type of enzyme that plays a crucial role in cell division and the regulation of the cell cycle. It is a serine/threonine protein kinase that is activated during the G2 phase of the cell cycle and is responsible for the initiation of mitosis. CDC2 is also involved in the regulation of DNA replication and the maintenance of genomic stability. In the medical field, CDC2 Protein Kinase is often studied in the context of cancer research, as its dysregulation has been linked to the development and progression of various types of cancer.

Cyclin-dependent kinase inhibitor p21 (p21) is a protein that plays a role in regulating the cell cycle, which is the process by which cells divide and grow. It is encoded by the CDKN1A gene and is a member of the Cip/Kip family of cyclin-dependent kinase inhibitors. In the cell cycle, the progression from one phase to the next is controlled by a series of checkpoints that ensure that the cell is ready to proceed. One of the key regulators of these checkpoints is the cyclin-dependent kinase (CDK) family of enzymes. CDKs are activated by binding to cyclins, which are proteins that are synthesized and degraded in a cyclic manner throughout the cell cycle. p21 acts as a CDK inhibitor by binding to and inhibiting the activity of cyclin-CDK complexes. This prevents the complexes from phosphorylating target proteins that are required for the progression of the cell cycle. As a result, p21 helps to prevent the cell from dividing when it is not ready, and it plays a role in preventing the development of cancer. In addition to its role in regulating the cell cycle, p21 has been implicated in a number of other cellular processes, including DNA repair, senescence, and apoptosis (programmed cell death). It is also involved in the response of cells to various stressors, such as DNA damage, oxidative stress, and hypoxia.

Protein-Serine-Threonine Kinases (PSTKs) are a family of enzymes that play a crucial role in regulating various cellular processes, including cell growth, differentiation, metabolism, and apoptosis. These enzymes phosphorylate specific amino acids, such as serine and threonine, on target proteins, thereby altering their activity, stability, or localization within the cell. PSTKs are involved in a wide range of diseases, including cancer, diabetes, cardiovascular disease, and neurodegenerative disorders. Therefore, understanding the function and regulation of PSTKs is important for developing new therapeutic strategies for these diseases.

Cyclin-dependent kinase inhibitor p27 (p27Kip1) is a protein that plays a role in regulating cell cycle progression. It is a member of the Cip/Kip family of cyclin-dependent kinase inhibitors, which also includes p21 and p57. In the cell cycle, the progression from one phase to the next is tightly regulated by a series of events that involve the activity of cyclin-dependent kinases (CDKs). CDKs are enzymes that are activated by binding to specific cyclins, which are proteins that are synthesized and degraded in a cyclic manner throughout the cell cycle. When CDKs are activated, they phosphorylate target proteins, which can either promote or inhibit cell cycle progression. p27Kip1 acts as a CDK inhibitor by binding to and inhibiting the activity of CDKs. It is primarily expressed in cells that are in a non-dividing state, such as terminally differentiated cells and quiescent cells. In these cells, p27Kip1 helps to maintain the cell in a non-dividing state by inhibiting the activity of CDKs, which prevents the cell from entering the cell cycle. In contrast, p27Kip1 is downregulated or lost in many types of cancer cells, where it is often associated with increased cell proliferation and tumor growth. This suggests that p27Kip1 may play a role in the development and progression of cancer.

Proto-oncogenes are normal genes that are involved in regulating cell growth and division. When these genes are mutated or overexpressed, they can become oncogenes, which can lead to the development of cancer. Proto-oncogenes are also known as proto-oncogene proteins.

Tumor suppressor proteins are a group of proteins that play a crucial role in regulating cell growth and preventing the development of cancer. These proteins act as brakes on the cell cycle, preventing cells from dividing and multiplying uncontrollably. They also help to repair damaged DNA and prevent the formation of tumors. Tumor suppressor proteins are encoded by genes that are located on specific chromosomes. When these genes are functioning properly, they produce proteins that help to regulate cell growth and prevent the development of cancer. However, when these genes are mutated or damaged, the proteins they produce may not function properly, leading to uncontrolled cell growth and the development of cancer. There are many different tumor suppressor proteins, each with its own specific function. Some of the most well-known tumor suppressor proteins include p53, BRCA1, and BRCA2. These proteins are involved in regulating cell cycle checkpoints, repairing damaged DNA, and preventing the formation of tumors. In summary, tumor suppressor proteins are a group of proteins that play a critical role in regulating cell growth and preventing the development of cancer. When these proteins are functioning properly, they help to maintain the normal balance of cell growth and division, but when they are mutated or damaged, they can contribute to the development of cancer.

Cyclin I is a protein that plays a role in regulating the cell cycle, which is the process by which cells grow, divide, and replicate their genetic material. Cyclin I is a type of cyclin, which are proteins that bind to and activate cyclin-dependent kinases (CDKs), enzymes that control the progression of the cell cycle. Cyclin I is involved in the G1 phase of the cell cycle, which is the first phase of the cycle and is characterized by cell growth and preparation for DNA replication. During the G1 phase, cyclin I helps to activate CDK4 and CDK6, which in turn phosphorylate and activate other proteins that are necessary for the progression of the cell cycle. Disruptions in the regulation of cyclin I and CDKs can lead to uncontrolled cell growth and the development of cancer.

In the medical field, RNA, Messenger (mRNA) refers to a type of RNA molecule that carries genetic information from DNA in the nucleus of a cell to the ribosomes, where proteins are synthesized. During the process of transcription, the DNA sequence of a gene is copied into a complementary RNA sequence called messenger RNA (mRNA). This mRNA molecule then leaves the nucleus and travels to the cytoplasm of the cell, where it binds to ribosomes and serves as a template for the synthesis of a specific protein. The sequence of nucleotides in the mRNA molecule determines the sequence of amino acids in the protein that is synthesized. Therefore, changes in the sequence of nucleotides in the mRNA molecule can result in changes in the amino acid sequence of the protein, which can affect the function of the protein and potentially lead to disease. mRNA molecules are often used in medical research and therapy as a way to introduce new genetic information into cells. For example, mRNA vaccines work by introducing a small piece of mRNA that encodes for a specific protein, which triggers an immune response in the body.

Lymphoma, Mantle-Cell is a type of non-Hodgkin's lymphoma, which is a cancer that affects the lymphatic system. The lymphatic system is a part of the immune system that helps to fight infections and diseases. Mantle-cell lymphoma typically affects the lymph nodes in the neck, armpits, and groin, but it can also affect other parts of the body, such as the spleen, liver, and bone marrow. Mantle-cell lymphoma is a relatively rare type of lymphoma, accounting for about 5% of all cases of non-Hodgkin's lymphoma. It is more common in older adults, with an average age of diagnosis of around 65 years. The exact cause of mantle-cell lymphoma is not known, but it is believed to be related to genetic changes in the cells of the immune system. Treatment options for mantle-cell lymphoma include chemotherapy, radiation therapy, and targeted therapy. In some cases, a stem cell transplant may also be recommended. The prognosis for mantle-cell lymphoma varies depending on the stage of the disease and the response to treatment.

Cyclin-dependent kinase inhibitor p16, also known as CDKN2A or p16INK4a, is a protein that plays a crucial role in regulating the cell cycle and preventing uncontrolled cell growth. It is encoded by the CDKN2A gene and is a member of the cyclin-dependent kinase inhibitor (CKI) family. In normal cells, p16 is expressed in response to DNA damage and acts as a brake on the cell cycle by inhibiting the activity of cyclin-dependent kinases (CDKs), which are enzymes that control cell cycle progression. When cells are damaged, p16 is activated and binds to CDK4 and CDK6, preventing them from phosphorylating and activating the retinoblastoma protein (Rb), which is a key regulator of the cell cycle. However, in many types of cancer, the CDKN2A gene is mutated or deleted, leading to a loss of p16 expression and allowing cells to bypass the cell cycle checkpoint controlled by p16. This can result in uncontrolled cell growth and the development of tumors. Therefore, p16 is considered a tumor suppressor gene, and its loss of function is associated with an increased risk of developing various types of cancer, including melanoma, lung cancer, and pancreatic cancer. In addition, p16 is also used as a diagnostic and prognostic marker in cancer, as its expression levels can be used to predict the aggressiveness of tumors and the response to treatment.

Proliferating Cell Nuclear Antigen (PCNA) is a protein that plays a crucial role in DNA replication and repair in cells. It is also known as Replication Factor C (RFC) subunit 4 or proliferating cell nuclear antigen-like 1 (PCNA-like 1). PCNA is a highly conserved protein that is found in all eukaryotic cells. It is a homotrimeric protein, meaning that it is composed of three identical subunits. Each subunit has a central channel that can bind to DNA, and it is this channel that is responsible for the interaction of PCNA with other proteins involved in DNA replication and repair. During DNA replication, PCNA forms a complex with other proteins, including DNA polymerase δ and the replication factor C (RFC) complex. This complex is responsible for unwinding the DNA double helix, synthesizing new DNA strands, and ensuring that the newly synthesized strands are correctly paired with the template strands. PCNA is also involved in DNA repair processes, particularly in the repair of DNA damage caused by ultraviolet (UV) radiation. In this context, PCNA interacts with other proteins, such as the X-ray repair cross-complementing protein 1 (XRCC1), to facilitate the repair of DNA damage. Overall, PCNA is a critical protein in the maintenance of genomic stability and the prevention of DNA damage-induced diseases, such as cancer.

E2F transcription factors are a family of proteins that play a critical role in regulating the cell cycle and controlling cell proliferation. They are named for their ability to bind to the E2 promoter region of genes that are involved in cell cycle progression. There are six known E2F transcription factors in humans, which are classified into three groups: E2F1-3, DP1-3, and E4F1. E2F1-3 are primarily involved in regulating cell cycle progression, while DP1-3 are required for the formation of stable E2F-DP complexes that are necessary for transcriptional activation. E4F1 is a transcriptional repressor that is involved in regulating DNA repair and cell death. E2F transcription factors are activated by the binding of cyclin-dependent kinases (CDKs) to cyclins, which occur during the G1 phase of the cell cycle. Once activated, E2F transcription factors bind to specific DNA sequences and promote the transcription of genes involved in cell cycle progression, such as those encoding cyclins and other cell cycle regulators. Abnormal regulation of E2F transcription factors has been implicated in a variety of human diseases, including cancer. For example, overexpression of E2F1 has been associated with the development of several types of cancer, including breast, lung, and ovarian cancer. Conversely, loss of E2F1 function has been shown to inhibit tumor growth and improve the efficacy of cancer therapies.

Beta-catenin is a protein that plays a crucial role in the regulation of cell adhesion and signaling pathways in the body. In the medical field, beta-catenin is often studied in the context of cancer, as mutations in the beta-catenin gene (CTNNB1) can lead to the development of various types of cancer, including colorectal cancer, endometrial cancer, and ovarian cancer. In normal cells, beta-catenin is a component of the cadherin adhesion complex, which helps cells stick together and maintain tissue integrity. However, in cancer cells, mutations in the beta-catenin gene can lead to the accumulation of beta-catenin in the cytoplasm and nucleus, where it can activate downstream signaling pathways that promote cell proliferation and survival. Beta-catenin is also involved in the regulation of other cellular processes, such as cell migration, differentiation, and apoptosis. As such, it is a potential target for the development of new cancer therapies.

Cyclin-dependent kinase 6 (CDK6) is an enzyme that plays a critical role in cell cycle regulation. It is a member of the cyclin-dependent kinase (CDK) family, which are regulatory enzymes that control the progression of cells through the different phases of the cell cycle. CDK6 is activated by binding to cyclin D, a regulatory protein that is expressed during the G1 phase of the cell cycle. Once activated, CDK6 phosphorylates a number of target proteins, including the retinoblastoma protein (Rb), which is a key regulator of the G1/S transition. Phosphorylation of Rb leads to its inactivation, allowing the cell to progress through the G1 phase and enter the S phase of the cell cycle. CDK6 is also involved in the regulation of other cellular processes, including DNA replication, transcription, and cell proliferation. Dysregulation of CDK6 activity has been implicated in the development of a number of human diseases, including cancer. For example, overexpression of CDK6 has been observed in many types of cancer, and it is thought to contribute to the uncontrolled cell proliferation that characterizes these diseases.

Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences and controlling the transcription of genetic information from DNA to RNA. They play a crucial role in the development and function of cells and tissues in the body. In the medical field, transcription factors are often studied as potential targets for the treatment of diseases such as cancer, where their activity is often dysregulated. For example, some transcription factors are overexpressed in certain types of cancer cells, and inhibiting their activity may help to slow or stop the growth of these cells. Transcription factors are also important in the development of stem cells, which have the ability to differentiate into a wide variety of cell types. By understanding how transcription factors regulate gene expression in stem cells, researchers may be able to develop new therapies for diseases such as diabetes and heart disease. Overall, transcription factors are a critical component of gene regulation and have important implications for the development and treatment of many diseases.

Glycogen Synthase Kinase 3 (GSK3) is a family of serine/threonine protein kinases that play a crucial role in various cellular processes, including metabolism, cell signaling, and gene expression. In the medical field, GSK3 has been implicated in the development and progression of several diseases, including diabetes, neurodegenerative disorders, and cancer. GSK3 is activated by various stimuli, including stress, inflammation, and insulin resistance, and its activity is regulated by phosphorylation and dephosphorylation. When activated, GSK3 phosphorylates and inactivates glycogen synthase, the enzyme responsible for glycogen synthesis, leading to reduced glycogen storage in the liver and muscles. This can contribute to the development of diabetes and other metabolic disorders. In addition to its role in metabolism, GSK3 has also been implicated in the regulation of cell signaling pathways, including the Wnt signaling pathway, which plays a critical role in cell proliferation, differentiation, and survival. Dysregulation of GSK3 activity in the Wnt signaling pathway has been implicated in the development of several types of cancer, including colon, breast, and ovarian cancer. Overall, GSK3 is a key regulator of cellular processes and its dysregulation has been implicated in the development and progression of several diseases. As such, it is an important target for the development of new therapeutic strategies for these diseases.

Ki-67 is a protein found in the nuclei of cells that are actively dividing. It is a useful marker for assessing the growth rate of tumors and is often used in conjunction with other markers to help diagnose and predict the behavior of cancer. The Ki-67 antigen is named after the Danish pathologist, Kai Erik Nielsen, who first described it in the 1980s. It is typically measured using immunohistochemistry, a technique that uses antibodies to detect specific proteins in tissue samples.

Cell transformation, neoplastic refers to the process by which normal cells in the body undergo genetic changes that cause them to become cancerous or malignant. This process involves the accumulation of mutations in genes that regulate cell growth, division, and death, leading to uncontrolled cell proliferation and the formation of tumors. Neoplastic transformation can occur in any type of cell in the body, and it can be caused by a variety of factors, including exposure to carcinogens, radiation, viruses, and inherited genetic mutations. Once a cell has undergone neoplastic transformation, it can continue to divide and grow uncontrollably, invading nearby tissues and spreading to other parts of the body through the bloodstream or lymphatic system. The diagnosis of neoplastic transformation typically involves a combination of clinical examination, imaging studies, and biopsy. Treatment options for neoplastic transformation depend on the type and stage of cancer, as well as the patient's overall health and preferences. Common treatments include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.

Breast neoplasms refer to abnormal growths or tumors in the breast tissue. These growths can be benign (non-cancerous) or malignant (cancerous). Benign breast neoplasms are usually not life-threatening, but they can cause discomfort or cosmetic concerns. Malignant breast neoplasms, on the other hand, can spread to other parts of the body and are considered a serious health threat. Some common types of breast neoplasms include fibroadenomas, ductal carcinoma in situ (DCIS), invasive ductal carcinoma, and invasive lobular carcinoma.

F-box proteins are a family of proteins that play a role in the regulation of protein degradation in cells. They are involved in the ubiquitin-proteasome pathway, which is the primary mechanism by which cells degrade and recycle proteins. F-box proteins are characterized by an F-box domain, which is a protein-protein interaction module that binds to other proteins, often through their ubiquitin modification. F-box proteins are often components of larger protein complexes, such as the SCF (Skp1-Cullin-F-box) complex, which is involved in the degradation of specific target proteins. Dysregulation of F-box proteins has been implicated in a number of diseases, including cancer, neurodegenerative disorders, and developmental disorders.

Tumor suppressor protein p53 is a protein that plays a crucial role in regulating cell growth and preventing the development of cancer. It is encoded by the TP53 gene and is one of the most commonly mutated genes in human cancer. The p53 protein acts as a "guardian of the genome" by detecting DNA damage and initiating a series of cellular responses to repair the damage or trigger programmed cell death (apoptosis) if the damage is too severe. This helps to prevent the accumulation of mutations in the DNA that can lead to the development of cancer. In addition to its role in preventing cancer, p53 also plays a role in regulating cell cycle progression, DNA repair, and the response to cellular stress. Mutations in the TP53 gene can lead to the production of a non-functional or mutated p53 protein, which can result in the loss of these important functions and contribute to the development of cancer. Overall, the p53 protein is a critical regulator of cell growth and survival, and its dysfunction is a common feature of many types of cancer.

DNA-binding proteins are a class of proteins that interact with DNA molecules to regulate gene expression. These proteins recognize specific DNA sequences and bind to them, thereby affecting the transcription of genes into messenger RNA (mRNA) and ultimately the production of proteins. DNA-binding proteins play a crucial role in many biological processes, including cell division, differentiation, and development. They can act as activators or repressors of gene expression, depending on the specific DNA sequence they bind to and the cellular context in which they are expressed. Examples of DNA-binding proteins include transcription factors, histones, and non-histone chromosomal proteins. Transcription factors are proteins that bind to specific DNA sequences and regulate the transcription of genes by recruiting RNA polymerase and other factors to the promoter region of a gene. Histones are proteins that package DNA into chromatin, and non-histone chromosomal proteins help to organize and regulate chromatin structure. DNA-binding proteins are important targets for drug discovery and development, as they play a central role in many diseases, including cancer, genetic disorders, and infectious diseases.

RNA, Small Interfering (siRNA) is a type of non-coding RNA molecule that plays a role in gene regulation. siRNA is approximately 21-25 nucleotides in length and is derived from double-stranded RNA (dsRNA) molecules. In the medical field, siRNA is used as a tool for gene silencing, which involves inhibiting the expression of specific genes. This is achieved by introducing siRNA molecules that are complementary to the target mRNA sequence, leading to the degradation of the mRNA and subsequent inhibition of protein synthesis. siRNA has potential applications in the treatment of various diseases, including cancer, viral infections, and genetic disorders. It is also used in research to study gene function and regulation. However, the use of siRNA in medicine is still in its early stages, and there are several challenges that need to be addressed before it can be widely used in clinical practice.

Proto-oncogene proteins c-myc is a family of proteins that play a role in regulating cell growth and division. They are also known as myc proteins. The c-myc protein is encoded by the MYC gene, which is located on chromosome 8. The c-myc protein is a transcription factor, which means that it helps to regulate the expression of other genes. When the c-myc protein is overexpressed or mutated, it can contribute to the development of cancer. In normal cells, the c-myc protein helps to control the cell cycle and prevent uncontrolled cell growth. However, in cancer cells, the c-myc protein may be overactive or mutated, leading to uncontrolled cell growth and the formation of tumors.

E2F1 transcription factor is a protein that plays a crucial role in regulating the cell cycle and cell proliferation. It is a member of the E2F family of transcription factors, which are involved in controlling the expression of genes that are necessary for cell cycle progression and DNA replication. E2F1 is activated during the G1 phase of the cell cycle, when the cell is preparing to divide. It binds to specific DNA sequences in the promoter regions of target genes, such as those involved in DNA replication and cell cycle progression, and promotes their transcription. In this way, E2F1 helps to coordinate the various events that occur during the cell cycle and ensure that the cell divides properly. Abnormal regulation of E2F1 has been implicated in a number of diseases, including cancer. For example, overexpression of E2F1 has been observed in many types of cancer, and it is thought to contribute to the uncontrolled proliferation of cancer cells. Conversely, loss of E2F1 function has been associated with impaired cell cycle progression and reduced cell proliferation, which may contribute to the development of certain types of cancer. Overall, E2F1 transcription factor plays a critical role in regulating the cell cycle and cell proliferation, and its dysregulation has been implicated in a number of diseases, including cancer.

Nuclear proteins are proteins that are found within the nucleus of a cell. The nucleus is the control center of the cell, where genetic material is stored and regulated. Nuclear proteins play a crucial role in many cellular processes, including DNA replication, transcription, and gene regulation. There are many different types of nuclear proteins, each with its own specific function. Some nuclear proteins are involved in the structure and organization of the nucleus itself, while others are involved in the regulation of gene expression. Nuclear proteins can also interact with other proteins, DNA, and RNA molecules to carry out their functions. In the medical field, nuclear proteins are often studied in the context of diseases such as cancer, where changes in the expression or function of nuclear proteins can contribute to the development and progression of the disease. Additionally, nuclear proteins are important targets for drug development, as they can be targeted to treat a variety of diseases.

Transcription factor DP1 is a protein that plays a role in regulating gene expression. It is a member of the basic helix-loop-helix (bHLH) family of transcription factors, which are proteins that bind to specific DNA sequences and help to control the transcription of genes. DP1 is encoded by the "DPF1" gene, which is located on chromosome 12 in humans. DP1 is involved in the development and differentiation of various cell types, including neurons, muscle cells, and immune cells. It has been implicated in a number of different diseases, including cancer, neurological disorders, and autoimmune diseases. For example, mutations in the "DPF1" gene have been associated with an increased risk of developing certain types of cancer, such as breast cancer and ovarian cancer. Additionally, DP1 has been shown to play a role in the development of multiple sclerosis, an autoimmune disorder that affects the central nervous system.

Retinoblastoma-like protein p107 (p107) is a protein that plays a role in regulating cell cycle progression and cell differentiation. It is a member of the retinoblastoma protein family, which includes other proteins such as pRb and p130. Like other members of this family, p107 is involved in the regulation of the G1/S transition of the cell cycle, which is the process by which cells prepare to divide. It does this by binding to specific DNA sequences and inhibiting the activity of proteins that promote cell cycle progression. In addition to its role in cell cycle regulation, p107 has also been implicated in the regulation of cell differentiation and the development of certain types of cancer.

CDC25 phosphatases are a family of enzymes that play a critical role in regulating cell cycle progression in eukaryotic cells. These enzymes are named after the cell division cycle 25 (CDC25) gene family, which encodes for the phosphatases. CDC25 phosphatases are responsible for dephosphorylating tyrosine residues on cyclin-dependent kinases (CDKs), which are key regulators of cell cycle progression. By removing phosphate groups from CDKs, CDC25 phosphatases activate these enzymes, allowing them to phosphorylate and activate other proteins involved in cell cycle progression. In addition to their role in cell cycle regulation, CDC25 phosphatases have also been implicated in a variety of other cellular processes, including DNA repair, apoptosis, and cancer development. Dysregulation of CDC25 phosphatase activity has been linked to several types of cancer, including breast, ovarian, and colorectal cancer. Overall, CDC25 phosphatases are important regulators of cell cycle progression and have important implications for human health and disease.

Neoplasm proteins are proteins that are produced by cancer cells. These proteins are often abnormal and can contribute to the growth and spread of cancer. They can be detected in the blood or other body fluids, and their presence can be used as a diagnostic tool for cancer. Some neoplasm proteins are also being studied as potential targets for cancer treatment.

Retinoblastoma-Binding Protein 1 (RBBP1) is a protein that plays a role in the regulation of gene expression. It is encoded by the RBBP1 gene and is found in the nucleus of cells. RBBP1 is a component of the Retinoblastoma protein (pRb) pathway, which is involved in the regulation of the cell cycle and the prevention of uncontrolled cell growth. In the context of retinoblastoma, a type of eye cancer that occurs in children, RBBP1 is thought to play a role in the development and progression of the disease.

The proteasome endopeptidase complex is a large protein complex found in the cells of all eukaryotic organisms. It is responsible for breaking down and recycling damaged or unnecessary proteins within the cell. The proteasome is composed of two main subunits: the 20S core particle, which contains the proteolytic active sites, and the 19S regulatory particle, which recognizes and unfolds target proteins for degradation. The proteasome plays a critical role in maintaining cellular homeostasis and is involved in a wide range of cellular processes, including cell cycle regulation, immune response, and protein quality control. Dysregulation of the proteasome has been implicated in a number of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

S-phase kinase-associated proteins (SKAPs) are a family of proteins that play a role in regulating the progression of the cell cycle, specifically during the S phase (DNA synthesis phase). They are involved in the regulation of DNA replication and repair, and are also implicated in the development of certain types of cancer. SKAPs are activated by the cyclin-dependent kinase (CDK) complex, which is a key regulator of the cell cycle. Dysregulation of SKAPs has been linked to various cellular processes, including cell proliferation, apoptosis, and differentiation.

In the medical field, "trans-activators" refer to proteins or molecules that activate the transcription of a gene, which is the process by which the information in a gene is used to produce a functional product, such as a protein. Trans-activators can bind to specific DNA sequences near a gene and recruit other proteins, such as RNA polymerase, to initiate transcription. They can also modify the chromatin structure around a gene to make it more accessible to transcription machinery. Trans-activators play important roles in regulating gene expression and are involved in many biological processes, including development, differentiation, and disease.

Recombinant fusion proteins are proteins that are produced by combining two or more genes in a single molecule. These proteins are typically created using genetic engineering techniques, such as recombinant DNA technology, to insert one or more genes into a host organism, such as bacteria or yeast, which then produces the fusion protein. Fusion proteins are often used in medical research and drug development because they can have unique properties that are not present in the individual proteins that make up the fusion. For example, a fusion protein might be designed to have increased stability, improved solubility, or enhanced targeting to specific cells or tissues. Recombinant fusion proteins have a wide range of applications in medicine, including as therapeutic agents, diagnostic tools, and research reagents. Some examples of recombinant fusion proteins used in medicine include antibodies, growth factors, and cytokines.

Proto-oncogene proteins c-akt, also known as protein kinase B (PKB), is a serine/threonine kinase that plays a critical role in various cellular processes, including cell survival, proliferation, and metabolism. It is a member of the Akt family of kinases, which are activated by various growth factors and cytokines. In the context of cancer, c-akt has been shown to be frequently activated in many types of tumors and is often associated with poor prognosis. Activation of c-akt can lead to increased cell survival and resistance to apoptosis, which can contribute to tumor growth and progression. Additionally, c-akt has been implicated in the regulation of angiogenesis, invasion, and metastasis, further contributing to the development and progression of cancer. Therefore, the study of c-akt and its role in cancer has become an important area of research in the medical field, with the goal of developing targeted therapies to inhibit its activity and potentially treat cancer.

DNA primers are short, single-stranded DNA molecules that are used in a variety of molecular biology techniques, including polymerase chain reaction (PCR) and DNA sequencing. They are designed to bind to specific regions of a DNA molecule, and are used to initiate the synthesis of new DNA strands. In PCR, DNA primers are used to amplify specific regions of DNA by providing a starting point for the polymerase enzyme to begin synthesizing new DNA strands. The primers are complementary to the target DNA sequence, and are added to the reaction mixture along with the DNA template, nucleotides, and polymerase enzyme. The polymerase enzyme uses the primers as a template to synthesize new DNA strands, which are then extended by the addition of more nucleotides. This process is repeated multiple times, resulting in the amplification of the target DNA sequence. DNA primers are also used in DNA sequencing to identify the order of nucleotides in a DNA molecule. In this application, the primers are designed to bind to specific regions of the DNA molecule, and are used to initiate the synthesis of short DNA fragments. The fragments are then sequenced using a variety of techniques, such as Sanger sequencing or next-generation sequencing. Overall, DNA primers are an important tool in molecular biology, and are used in a wide range of applications to study and manipulate DNA.

Protein kinases are enzymes that catalyze the transfer of a phosphate group from ATP (adenosine triphosphate) to specific amino acid residues on proteins. This process, known as phosphorylation, can alter the activity, localization, or stability of the target protein, and is a key mechanism for regulating many cellular processes, including cell growth, differentiation, metabolism, and signaling pathways. Protein kinases are classified into different families based on their sequence, structure, and substrate specificity. Some of the major families of protein kinases include serine/threonine kinases, tyrosine kinases, and dual-specificity kinases. Each family has its own unique functions and roles in cellular signaling. In the medical field, protein kinases are important targets for the development of drugs for the treatment of various diseases, including cancer, diabetes, and cardiovascular disease. Many cancer drugs target specific protein kinases that are overactive in cancer cells, while drugs for diabetes and cardiovascular disease often target kinases involved in glucose metabolism and blood vessel function, respectively.

Microtubule-associated proteins (MAPs) are a group of proteins that bind to microtubules, which are important components of the cytoskeleton in cells. These proteins play a crucial role in regulating the dynamics of microtubules, including their assembly, disassembly, and stability. MAPs are involved in a wide range of cellular processes, including cell division, intracellular transport, and the maintenance of cell shape. They can also play a role in the development of diseases such as cancer, where the abnormal regulation of microtubules and MAPs can contribute to the growth and spread of tumors. There are many different types of MAPs, each with its own specific functions and mechanisms of action. Some MAPs are involved in regulating the dynamics of microtubules, while others are involved in the transport of molecules along microtubules. Some MAPs are also involved in the organization and function of the mitotic spindle, which is essential for the proper segregation of chromosomes during cell division. Overall, MAPs are important regulators of microtubule dynamics and play a crucial role in many cellular processes. Understanding the function of these proteins is important for developing new treatments for diseases that are associated with abnormal microtubule regulation.

Protamine kinase is an enzyme that is involved in the regulation of blood clotting. It is responsible for converting protamine sulfate, a substance that is used to neutralize the anticoagulant effects of heparin, into protamine. Protamine sulfate is often used in conjunction with heparin during medical procedures, such as surgery or catheterization, to prevent excessive bleeding. Protamine kinase helps to ensure that the appropriate amount of protamine is present to neutralize the heparin, preventing the formation of blood clots.

In the medical field, carrier proteins are proteins that transport molecules across cell membranes or within cells. These proteins bind to specific molecules, such as hormones, nutrients, or waste products, and facilitate their movement across the membrane or within the cell. Carrier proteins play a crucial role in maintaining the proper balance of molecules within cells and between cells. They are involved in a wide range of physiological processes, including nutrient absorption, hormone regulation, and waste elimination. There are several types of carrier proteins, including facilitated diffusion carriers, active transport carriers, and ion channels. Each type of carrier protein has a specific function and mechanism of action. Understanding the role of carrier proteins in the body is important for diagnosing and treating various medical conditions, such as genetic disorders, metabolic disorders, and neurological disorders.

Cyclin-dependent kinase inhibitors (CDKIs) are a group of proteins that regulate the cell cycle by inhibiting the activity of cyclin-dependent kinases (CDKs). CDKs are a family of enzymes that play a critical role in regulating cell cycle progression by phosphorylating target proteins. CDKIs bind to CDKs and prevent them from phosphorylating their target proteins, thereby inhibiting cell cycle progression. CDKIs are important regulators of cell cycle progression and are involved in a variety of cellular processes, including DNA replication, chromosome segregation, and apoptosis. Dysregulation of CDKIs has been implicated in a number of diseases, including cancer, where the overexpression or loss of function of CDKIs can lead to uncontrolled cell proliferation and the development of tumors. CDKIs are classified into two main groups: the INK4 family (p16INK4a, p15INK4b, p18INK4c, and p19INK4d) and the Cip/Kip family (p21Cip1, p27Kip1, and p57Kip2). The INK4 family members are primarily involved in inhibiting CDK4 and CDK6, while the Cip/Kip family members can inhibit multiple CDKs.

Threonine is an essential amino acid that plays a crucial role in various biological processes in the human body. It is a polar amino acid with a hydroxyl group (-OH) attached to the alpha carbon atom, which makes it hydrophilic and capable of forming hydrogen bonds. In the medical field, threonine is important for several reasons. Firstly, it is a building block of proteins, which are essential for the structure and function of cells and tissues in the body. Secondly, threonine is involved in the metabolism of carbohydrates and lipids, which are important sources of energy for the body. Thirdly, threonine is a precursor for the synthesis of several important molecules, including carnitine, which plays a role in the metabolism of fatty acids. Threonine deficiency can lead to a range of health problems, including muscle wasting, impaired growth and development, and weakened immune function. It is therefore important to ensure that the body receives adequate amounts of threonine through a balanced diet or supplements.

Carcinoma, Squamous Cell is a type of cancer that originates in the squamous cells, which are thin, flat cells that line the surface of the body. Squamous cells are found in the skin, mouth, throat, lungs, and other organs. Carcinoma, Squamous Cell can develop in any part of the body where squamous cells are present, but it is most commonly found in the head and neck, lungs, and skin. The exact cause of Squamous Cell Carcinoma is not always clear, but it is often associated with exposure to certain substances, such as tobacco smoke, alcohol, and certain chemicals. It can also develop as a result of chronic inflammation or infection, such as HPV (human papillomavirus) infection in the cervix. Symptoms of Squamous Cell Carcinoma can vary depending on the location of the tumor, but may include a persistent sore or lesion that does not heal, a change in the appearance of the skin or mucous membranes, difficulty swallowing or breathing, and unexplained weight loss. Treatment for Squamous Cell Carcinoma typically involves surgery to remove the tumor, followed by radiation therapy or chemotherapy to kill any remaining cancer cells. In some cases, targeted therapy or immunotherapy may also be used. The prognosis for Squamous Cell Carcinoma depends on the stage of the cancer at the time of diagnosis and the overall health of the patient.

Phosphatidylinositol 3-kinases (PI3Ks) are a family of enzymes that play a critical role in cellular signaling pathways. They are involved in a wide range of cellular processes, including cell growth, proliferation, differentiation, survival, migration, and metabolism. PI3Ks are activated by various extracellular signals, such as growth factors, hormones, and neurotransmitters, and they generate second messengers by phosphorylating phosphatidylinositol lipids on the inner leaflet of the plasma membrane. This leads to the recruitment and activation of downstream effector molecules, such as protein kinases and phosphatases, which regulate various cellular processes. Dysregulation of PI3K signaling has been implicated in the development of various diseases, including cancer, diabetes, and neurological disorders. Therefore, PI3Ks are important targets for the development of therapeutic agents for these diseases.

Maturation-Promoting Factor (MPF) is a complex of proteins that plays a crucial role in the regulation of cell cycle progression and the initiation of mitosis in eukaryotic cells. It is composed of two subunits: cyclin B and cyclin-dependent kinase (CDK1). During the cell cycle, MPF is synthesized and activated during the G2 phase, and it remains active until the end of mitosis. MPF promotes the progression of the cell cycle by phosphorylating various target proteins, including the nuclear envelope, kinetochores, and other cell cycle regulators. MPF is also involved in the regulation of apoptosis, the process of programmed cell death. When cells are damaged or stressed, MPF can be activated to trigger apoptosis, which helps to eliminate damaged or abnormal cells. In the medical field, MPF is of interest because it plays a critical role in the development and progression of many diseases, including cancer. Abnormal regulation of MPF activity has been linked to the development of various types of cancer, and targeting MPF has been proposed as a potential therapeutic strategy for cancer treatment.

Mitogen-Activated Protein Kinases (MAPKs) are a family of enzymes that play a crucial role in cellular signaling pathways. They are involved in regulating various cellular processes such as cell growth, differentiation, proliferation, survival, and apoptosis. MAPKs are activated by extracellular signals such as growth factors, cytokines, and hormones, which bind to specific receptors on the cell surface. This activation leads to a cascade of phosphorylation events, where MAPKs phosphorylate and activate downstream effector molecules, such as transcription factors, that regulate gene expression. In the medical field, MAPKs are of great interest due to their involvement in various diseases, including cancer, inflammatory disorders, and neurological disorders. For example, mutations in MAPK signaling pathways are commonly found in many types of cancer, and targeting these pathways has become an important strategy for cancer therapy. Additionally, MAPKs are involved in the regulation of immune responses, and dysregulation of these pathways has been implicated in various inflammatory disorders. Finally, MAPKs play a role in the development and maintenance of the nervous system, and dysfunction of these pathways has been linked to neurological disorders such as Alzheimer's disease and Parkinson's disease.

Luciferases are enzymes that catalyze the oxidation of luciferin, a small molecule, to produce light. In the medical field, luciferases are commonly used as reporters in bioluminescence assays, which are used to measure gene expression, protein-protein interactions, and other biological processes. One of the most well-known examples of luciferases in medicine is the green fluorescent protein (GFP) luciferase, which is derived from the jellyfish Aequorea victoria. GFP luciferase is used in a variety of applications, including monitoring gene expression in living cells and tissues, tracking the movement of cells and proteins in vivo, and studying the dynamics of signaling pathways. Another example of a luciferase used in medicine is the firefly luciferase, which is derived from the firefly Photinus pyralis. Firefly luciferase is used in bioluminescence assays to measure the activity of various enzymes and to study the metabolism of drugs and other compounds. Overall, luciferases are valuable tools in the medical field because they allow researchers to visualize and quantify biological processes in a non-invasive and sensitive manner.

DNA, or deoxyribonucleic acid, is a molecule that carries genetic information in living organisms. It is composed of four types of nitrogen-containing molecules called nucleotides, which are arranged in a specific sequence to form the genetic code. In the medical field, DNA is often studied as a tool for understanding and diagnosing genetic disorders. Genetic disorders are caused by changes in the DNA sequence that can affect the function of genes, leading to a variety of health problems. By analyzing DNA, doctors and researchers can identify specific genetic mutations that may be responsible for a particular disorder, and develop targeted treatments or therapies to address the underlying cause of the condition. DNA is also used in forensic science to identify individuals based on their unique genetic fingerprint. This is because each person's DNA sequence is unique, and can be used to distinguish one individual from another. DNA analysis is also used in criminal investigations to help solve crimes by linking DNA evidence to suspects or victims.

Cyclin-dependent kinase 9 (CDK9) is an enzyme that plays a crucial role in regulating gene expression by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (Pol II). CDK9 is a component of the positive transcription elongation factor b (P-TEFb) complex, which is responsible for promoting the transition of Pol II from initiation to elongation during transcription. CDK9 is activated by the cyclin T1 or cyclin T2 proteins, which bind to the kinase and stimulate its activity. The P-TEFb complex is involved in the regulation of many genes, including those involved in cell proliferation, differentiation, and survival. Dysregulation of CDK9 activity has been implicated in various diseases, including cancer, HIV infection, and neurological disorders. CDK9 inhibitors are being developed as potential therapeutic agents for the treatment of various diseases, including cancer and HIV infection. These inhibitors target the interaction between CDK9 and its cyclin partners, thereby inhibiting the activity of the P-TEFb complex and blocking transcription.

Bromodeoxyuridine (BrdU) is a synthetic analog of the nucleoside thymidine, which is a building block of DNA. It is commonly used in the medical field as a marker for DNA synthesis and cell proliferation. BrdU is incorporated into newly synthesized DNA during the S phase of the cell cycle, when DNA replication occurs. This makes it possible to detect cells that are actively dividing by staining for BrdU. BrdU staining is often used in immunohistochemistry and flow cytometry to study the proliferation of cells in various tissues and organs, including the brain, bone marrow, and skin. BrdU is also used in some cancer treatments, such as chemotherapy and radiation therapy, to target rapidly dividing cancer cells. By inhibiting DNA synthesis, BrdU can slow down or stop the growth of cancer cells, making them more susceptible to treatment. However, it is important to note that BrdU can also cause DNA damage and has been associated with an increased risk of cancer in some studies. Therefore, its use in medical research and treatment should be carefully monitored and regulated.

Ubiquitins are small, highly conserved proteins that are involved in a variety of cellular processes, including protein degradation, signal transduction, and gene expression. In the medical field, ubiquitins are often studied in the context of diseases such as cancer, neurodegenerative disorders, and autoimmune diseases. One of the key functions of ubiquitins is to mark proteins for degradation by the proteasome, a large protein complex that breaks down and removes damaged or unnecessary proteins from the cell. This process is essential for maintaining cellular homeostasis and regulating the levels of specific proteins in the cell. In addition to their role in protein degradation, ubiquitins are also involved in a number of other cellular processes, including cell cycle regulation, DNA repair, and immune response. Dysregulation of ubiquitin-mediated processes has been implicated in a variety of diseases, including cancer, where it can contribute to the development and progression of tumors. Overall, ubiquitins are an important class of proteins that play a critical role in many cellular processes, and their dysfunction can have significant consequences for human health.

E2F4 Transcription Factor is a protein that plays a role in regulating the cell cycle and cell proliferation. It is a member of the E2F family of transcription factors, which are involved in controlling the expression of genes that are necessary for cell division and growth. E2F4 is activated by the binding of other proteins, such as Cyclin E, and it in turn regulates the expression of genes that are necessary for the progression of the cell cycle. Dysregulation of E2F4 has been implicated in the development of various types of cancer, including breast, ovarian, and prostate cancer.

Ubiquitin-Protein Ligase Complexes (UPCs) are multi-protein complexes that play a crucial role in the process of protein degradation in cells. These complexes are responsible for attaching small protein molecules called ubiquitin to specific target proteins, which marks them for degradation by the proteasome, a large protein complex that breaks down proteins into smaller peptides. UPCs are composed of several subunits, including E1, E2, and E3 enzymes, which work together to transfer ubiquitin from one enzyme to another and ultimately to the target protein. The E1 enzyme activates ubiquitin, while the E2 enzyme binds to it and transfers it to the E3 enzyme, which recognizes the target protein and facilitates its ubiquitination. UPCs are involved in a wide range of cellular processes, including cell cycle regulation, DNA repair, and the regulation of protein levels. Dysregulation of UPCs has been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Therefore, understanding the function and regulation of UPCs is an important area of research in the medical field.

STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a critical role in regulating gene expression in response to various signaling pathways, including cytokines, growth factors, and hormones. In the medical field, STAT3 is often studied in the context of cancer, as it is frequently activated in many types of tumors and is involved in promoting cell proliferation, survival, and invasion. Dysregulation of STAT3 signaling has been implicated in the development and progression of various cancers, including breast, prostate, and lung cancer. Additionally, STAT3 has been shown to play a role in other diseases, such as autoimmune disorders and inflammatory diseases. Targeting STAT3 signaling is therefore an active area of research in the development of new cancer therapies and other treatments.

... cyclin D1 is translocated to the IgH promoter leading to cyclin D1 overexpression. Chromosomal translocation of the cyclin D1 ... Cyclin D1 is a protein that in humans is encoded by the CCND1 gene. The CCND1 gene encodes the cyclin D1 protein. The human ... Cyclin D1 and the mechanisms it regulates have the potential to be a therapeutic target for cancer drugs: Cyclin D1 has been ... Cyclin D1 has been found to be overexpressed in breast carcinoma. Its potential use as a biomarker was suggested. Cyclin D1 was ...
CDK6; cyclin D1, cyclin D2, cyclin D3 CDK7; cyclin H CDK8; cyclin C CDK9; cyclin T1, cyclin T2a, cyclin T2b, cyclin K CDK10 ... cyclin A, cyclin B CDK2; cyclin A, cyclin E CDK3; cyclin C CDK4; cyclin D1, cyclin D2, cyclin D3 CDK5; CDK5R1, CDK5R2. See also ... Furthermore, cyclin binding determines the specificity of the cyclin-CDK complex for particular substrates. Cyclins can ... Viruses can encode proteins with sequence homology to cyclins. One much-studied example is K-cyclin (or v-cyclin) from Kaposi ...
The overexpression of cyclin D1 is thought to be a major factor in the development of ISMCL and its progression to MCL. ... The cyclin D1-expressing lymphocytes generally populate the inner layers of the marginal zone but on occasion some of these ... "CCND1 cyclin D1 [Homo sapiens (human)] - Gene - NCBI". "TP53 tumor protein p53 [Homo sapiens (human)] - Gene - NCBI". "CDKN2B ... In consequence, CCND1 overexpresses cyclin D1, a protein which promotes the cell cycle and thereby cellular proliferation. ...
Jiang Q, Feng MG, Mo YY (June 2009). "Systematic validation of predicted microRNAs for cyclin D1". BMC Cancer. 9: 194. doi: ...
It has been shown to activate the cell division cycle 2, cyclin D1, and insulin-like growth factor-binding protein 5 genes. ... Horstmann S, Ferrari S, Klempnauer KH (January 2000). "Regulation of B-Myb activity by cyclin D1". Oncogene. 19 (2): 298-306. ... April 2001). "Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine ... The encoded protein is phosphorylated by cyclin A/cyclin-dependent kinase 2 during the S-phase of the cell cycle and possesses ...
LKB1 catalytic deficient mutants found in Peutz-Jeghers syndrome activate the expression of cyclin D1 through recruitment to ... Scott KD, Nath-Sain S, Agnew MD, Marignani PA (June 2007). "LKB1 catalytically deficient mutants enhance cyclin D1 expression ...
Jiang Q, Feng MG, Mo YY (2009). "Systematic validation of predicted microRNAs for cyclin D1". BMC Cancer. 9: 194. doi:10.1186/ ...
AKAP13 AHR BRCA1 CAV1 CCNC CDC25B CEBPB COBRA1 COUP-TFI CREBBP CRSP3 Cyclin D1 DDX17 DDX5 DNTTIP2 EP300 ESR2 FOXO1 GREB1 GTF2H1 ... "CDK-independent activation of estrogen receptor by cyclin D1". Cell. 88 (3): 405-415. doi:10.1016/S0092-8674(00)81879-6. hdl: ... March 2003). "MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates ... also a D1-like receptor full agonist (R,R)-Tetrahydrochrysene ((R,R)-THC) - actually not selective over ERβ, but rather an ...
Cyclin D1, Cyclin-dependent kinase 7, DACH1, Death associated protein 6, L-DOPA, EFCAB6, Epidermal growth factor receptor, ... Reutens AT, Watanabe G, Albanese C, McPhaul MJ, Balk SP, Pestell RG (1998). "Cyclin D1 binds activating mutants of the androgen ... "Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)- ... "A central domain of cyclin D1 mediates nuclear receptor corepressor activity". Oncogene. 24 (3): 431-44. doi:10.1038/sj.onc. ...
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) 2(1):14-21, 2009. Spitz MR, Hong ...
Mantle cell lymphoma is characterized by fusion of cyclin D1 to the immunoglobulin locus. Cyclin D1 inhibits Rb, a tumor ...
... can be associated with overexpression of the cyclin D1 gene. It is also associated with multiple endocrine ... Hsi ED, Zukerberg LR, Yang WI, Arnold A (May 1996). "Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical ...
Both MyoD and pRb are necessary for the repression of cyclin D1, but rather than acting directly on cyclin D1, they act on Fra- ... and thus cyclin D1) as either MyoD or pRb on its own is not sufficient alone to induce cyclin D1 repression and thus cell cycle ... This is done through regulation of the Cyclin, Cyclin D1. Cell cycle arrest (in which myoblasts would indicate the conclusion ... Zhang JM, Wei Q, Zhao X, Paterson BM (February 1999). "Coupling of the cell cycle and myogenesis through the cyclin D1- ...
Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, Asano G (Mar 1999). "Expression of hsp90 and cyclin D1 in human ... For example, the co-chaperone CDC37 (cell division cycle 37) stabilizes the cell cycle regulatory proteins CDK4 (cyclin ...
A Cyclin-dependent kinase 6 interacts with: CDKN2C, Cyclin D1, Cyclin D3, P16, PPM1B, and PPP2CA. Cell cycle Cyclin-dependent ... It is regulated by cyclins, more specifically by Cyclin D proteins and Cyclin-dependent kinase inhibitor proteins. The protein ... CDK6 is positively regulated primarily by its union to the D cyclins D1, D2 and D3. If this subunit of the complex is not ... In mammalian cells, cell cycle is activated by CDK6 in the early G1 phase through interactions with cyclins D1, D2 and D3. ...
Zhang JM, Wei Q, Zhao X, Paterson BM (1999). "Coupling of the cell cycle and myogenesis through the cyclin D1-dependent ... "Entrez Gene: CDK4 cyclin-dependent kinase 4". "CDK4 - Cyclin-dependent kinase 4 - Homo sapiens (Human) - CDK4 gene & protein". ... Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 ... 1993). "Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent ...
July 1997). "Identification of CDK4 sequences involved in cyclin D1 and p16 binding". The Journal of Biological Chemistry. 272 ... p21 p53 Cyclin-dependent kinase Cyclin D GRCh38: Ensembl release 89: ENSG00000147889 - Ensembl, May 2017 GRCm38: Ensembl ... "Entrez Gene: CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)". Nobori T, Miura K, Wu DJ, Lois A, ... p16 is an inhibitor of cyclin-dependent kinases (CDK). It slows down the cell cycle by prohibiting progression from G1 phase to ...
It, combined with the Ras pathway, downregulate cyclin D1, a cyclin-dependent kinase, if they are not stimulated by the ... In the presence of mitogens, sufficient cyclin D1 can be produced. This process cascades onwards, producing other cyclins which ... Smad proteins then trigger an increase in p15, which inhibits cyclin D1 and prevents cell cycle progression. In many cancers, ... and depends on cyclins to be passed. One of the most important of these is TP53, a gene which produces a family of proteins ...
Adnane J, Shao Z, Robbins PD (January 1999). "Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1- ... Siegert JL, Rushton JJ, Sellers WR, Kaelin WG, Robbins PD (November 2000). "Cyclin D1 suppresses retinoblastoma protein- ...
Immunostains for smooth muscle actin and cyclin D1 are characteristically positive. The main histologic differential diagnosis ...
It reduces the growth of new cells by inhibiting cyclin D1. As a result, cells arrest during G1 phase and enter apoptosis. ... "Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1". J. Biol. Chem. 277 (19): 16464-9. doi: ...
Mantle cell lymphoma is excluded due to the lack of CD5 and cyclin-D1 expression. Clonal rearrangements of the immunoglobulin ... July 1998). "Absence of cyclin D1 protein expression in splenic marginal zone lymphoma". Mod. Pathol. 11 (7): 601-6. PMID ... November 1999). "Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q ...
Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc.Natl.Acad.Sci.U.S.A 109, E3473- ...
Lin HM, Zhao L, Cheng SY (August 2002). "Cyclin D1 Is a Ligand-independent Co-repressor for Thyroid Hormone Receptors". J. Biol ... "A central domain of cyclin D1 mediates nuclear receptor corepressor activity". Oncogene. 24 (3): 431-44. doi:10.1038/sj.onc. ...
Cyclin-D1-binding protein 1 is a protein that in humans is encoded by the CCNDBP1 gene. This gene was identified by the ... CCNDBP1 has been shown to interact with GRAP2 and Cyclin D1. GRCh38: Ensembl release 89: ENSG00000166946 - Ensembl, May 2017 ... "Entrez Gene: CCNDBP1 cyclin D-type binding-protein 1". Xia, C; Bao Z; Tabassam F; Ma W; Qiu M; Hua S; Liu M (Jul 2000). "GCIP, ... Xia C, Bao Z, Tabassam F, Ma W, Qiu M, Hua S, Liu M (Aug 2000). "GCIP, a novel human grap2 and cyclin D interacting protein, ...
"Induction of cyclin D1 by simian virus 40 small tumor antigen". Proceedings of the National Academy of Sciences of the United ...
"Phosphorylation-dependent ubiquitination of cyclin D1 by the SCFFBX4-αBcrystallin complex". Mol. Cell. 24 (3): 355-66. doi: ...
... overexpression of FHL2 inhibit the proliferative activity of the HCC Hep3B cell line by decreasing its cyclin D1 expression and ... "Fos family members induce cell cycle entry by activating cyclin D1". Molecular and Cellular Biology. 18 (9): 5609-19. doi: ...
The lymphocytes have marker protein profiles (e.g. CD20 and Bcl-2 positive; CD5, cyclin D1 and CD10 negative) that are typical ... or cyclin D1 marker proteins along with some plasma cells and a variable number of reactive T-cells. Fifty percent of cases ... or cyclin D1.[citation needed] Some 6-19% of NMZL cases have been reported to be associated with autoimmune diseases such as ... marker proteins but do not express the cyclin D1 marker protein., the T-cell marker, CD10, or BCL6. There are various EMZL ...
Yoshihara T, Collado D, Hamaguchi M (2007). "Cyclin D1 down-regulation is essential for DBC2's tumor suppressor function". ...
Rabbit Monoclonal Cyclin D1 antibody [RM241]. Validated in WB, IHC-P. Tested in Human. ... There are currently no references for Cyclin D1 antibody [RM241] (GTX33611). Be the first to share your publications with this ... There are currently no reviews for Cyclin D1 antibody [RM241] (GTX33611). Be the first to share your experience with this ... IHC-P analysis of human mantle cell lymphoma tissue using GTX33611 Cyclin D1 antibody [RM241].. Dilution : 1:1000 ...
In this study, we used luciferease reporter assays to validate microRNAs that can silence cyclin D1 (CCND1) because CCND1 is a ... Systematic validation of predicted microRNAs for cyclin D1. Access & Citations. * 6908 Article Accesses. ...
... as well as an overexpression of cyclin D1. [11] Chen et al noted that the association with cyclin D1 overexpression in hairy ... Cyclin D1 plays a key role in cell cycle regulation and progression of cells from G1 phase to S phase by activation of cyclin- ... Cyclin D1 is overexpressed. Immunophenotyping helps differentiate MCL from other small B-cell lymphomas (see the Table, below). ... 11] Chen et al assessed expression of sox11 and evaluated its association with t(11;14) and overexpression of cyclin D1 in 211 ...
... modified nuclear cyclin D1 and inhibits retinoblastoma protein (Rb) phosphorylation. The lysine residue, K33, of cyclin D1 is a ... we show that nuclear cyclin D1 is far more potent than wild-type (WT) cyclin D1 in bypassing Ras-induced senescence. Thus, this ... study identifies SUMO modification as a positive regulator of nuclear cyclin D1, and reveals a new way by which cell cycle ... modified nuclear cyclin D1 and inhibits retinoblastoma protein (Rb) phosphorylation. The lysine residue, K33, of cyclin D1 is a ...
... Artemenko O.A. ... Artemenko O.A. Expression of d1- and d3-cyclin genes in pea (Pisum sativum L.) root meristem under clinorotation, Tsitol Genet ... Using in situ hybridization the d1- and d3-cyclin gene expression has been shown in pea (Pisum sativum L.) root meristem cells ... The delay of degradation of cyclin subunits is the cause of G1-phase prolongation under clinorotation leading to delay of pea ...
However, proliferation of cardiomyocytes induced by nuclear-targeted cyclin D1 (D1NLS) stops after one or two rounds of cell ... However, proliferation of cardiomyocytes induced by nuclear-targeted cyclin D1 (D1NLS) stops after one or two rounds of cell ... However, proliferation of cardiomyocytes induced by nuclear-targeted cyclin D1 (D1NLS) stops after one or two rounds of cell ... However, proliferation of cardiomyocytes induced by nuclear-targeted cyclin D1 (D1NLS) stops after one or two rounds of cell ...
Cyclin D1 and c-Myc are key participants in the cell-cycle pathway, in which aberrancies have been associated with malignant ... Although our preliminary results need to be validated in a larger number of tumors, the abnormal expression of cyclin D1 and c- ... No abnormal expression of cyclin D1 or c-Myc was demonstrated in any of the 12 normal ovarian specimens. However, compared to ... Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer ...
CDK4, CDK6, Cyclin D1 and Notch1 immunocytochemical expression of oral brush liquid-based cytology for the diagnosis of oral ... Dive into the research topics of CDK4, CDK6, Cyclin D1 and Notch1 immunocytochemical expression of oral brush liquid-based ...
We aimed to assess the diagnostic utility of Transgelin, Stathmin, BCOR and Cyclin-D1 separately and in-combinations in ... The combination of BCOR and Cyclin-D1 expression has high sensitivity and specificity for diagnosis of ESS and differentiating ... The diagnostic performances of Transgelin, Stathmin, BCOR and Cyclin-D1 were assessed in samples from all patients using ... The combination of Stathmin and Transgelin, BCOR and CyclinD1 expression has high sensitivity and specificity for diagnosis of ...
Results: It was shown that amplification of CCND1, a gene encoding cyclin D1, was more prevalent in parathyroid carcinomas than ...
Cyclin D1 [IHC452] CD138 [IHC138] * Additional comments or questions: * Which of the following best describes your role or ...
Cyclin D1 Positive Control Slides. View Price and Availability. Sigma-Aldrich. 246S ...
Recombinant Human E2F3 GST (N-Term) Protein. Backed by our 100% Guarantee.
Encodes cyclin D1. Involved in cell cycle regulation. Also called PRAD1. Breast and squamous cell carcinomas. 49 ... Inhibitor of cyclin-dependent kinases; regulates cell cycle passage from G1 into S.. Melanomas. 135 ... The product of the the p21 gene is a negative regulator of cyclin-dependent kinases, enzymes that are critical in the ...
The second cohort was required to have tumors that had an amplification of cyclin D1, loss of p16, or both. Both cohorts were ... The new drug acts as an inhibitor of cyclin-dependent kinases 4 and 6, which are involved in promoting the growth of cancer ... It was then decided that patient selection based on cyclin D amplification or p16 loss was not likely to improve patient ...
Croft DR, Olson MF . The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol ...
Moreover, under the influence of the PI3K-Akt pathway, the G1/S cell cycle progress through the upregulation of cyclin D1 ( ... Diehl, J. A., Cheng, M., Roussel, M. F., Sherr, C. J. (1998). Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and ...
K-ras gene mutations and cyclin D1 protein production were also identified in the colon tumours. The NTP (2008) concluded that ...
p21 - a cyclin-dependent kinase inhibitor - promotes cell cycle arrest. Cyclin D1 is a key regulator of the cell cycle and is ... EMC upregulates p21 and downregulates cyclin D1. Kojima and colleagues work in mice found EMC to be the active compound in ... Low doses of EMC were capable of suppressing cell proliferation by upregulating p21 and downregulating cyclin D1 expression. ... to report that the natural compound-induced decrease in TFAM expression correlates with the expression levels of cyclin D1 and ...
... inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247- ...
Additional IHC panel for subtyping: Cyclin D1, kappa/lambda, CD30, CD138, EBER-ISH, ALK, HHV8 ... Immunohistochemistry panel: CD20, CD3, CD5, CD10, BCL2, kappa/lambda, CD21 or CD23, BCL6, cyclin D1 ... Additional IHC panel for subtyping: Ki-67, CD43, CD21, CD23, Cyclin D1, kappa/lambda ... Immunohistochemistry panel: CD20, CD3, CD5, CD10, BCL2, BCL6, cyclin D1, CD21, CD23, Ki-67 ...
The most promising markers to date are the presence of aneuploidy, loss of heterozygosity of p53 and cyclin D1 overexpression. ...
Cyclin D1 adeno clamps. Completed. 182. 19633. Anand Narayanan. Determine lipid profiles in blood in TCF7l2 overexpression mice ...
Cyclin B1 (2) Cyclin D1 (6) Cytokeratin 10 (1) Cytokeratin 10/13 (1) ...
... apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1 ...
Prospective study of cyclin D1 overexpression in Barretts esophagus: association with increased risk of adenocarcinoma. J Natl ...
  • The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. (genetex.com)
  • The molecular consequence of translocation is overexpression of the protein cyclin D1 (coded by the PRAD1 gene located close to the breakpoint). (medscape.com)
  • Using in situ hybridization the d1- and d3-cyclin gene expression has been shown in pea ( Pisum sativum L.) root meristem cells under slow horizontal clinorotation and in the stationary conditions. (cytgen.com)
  • There was no significant difference of overexpression of cyclin D1 or c-Myc gene products between these four histologic subtypes of ovarian adenocarcinomas. (bmj.com)
  • It was shown that amplification of CCND1, a gene encoding cyclin D1, was more prevalent in parathyroid carcinomas than in adenomas (71 vs. 21 %, p = 0.056). (nih.gov)
  • MEN 4 is caused by an inactivating mutation of the CDKN1B gene, which codes for the cyclin dependent kinase inhibitor 1B protein, also known as p27 or p27KIP1. (msdmanuals.com)
  • However, compared to normal ovarian tissues, overexpression of cyclin D1 and c-Myc was observed in 42.6% (20/47) and 65.9% (31/47) of tumors examined, respectively. (bmj.com)
  • Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. (genetex.com)
  • No abnormal expression of cyclin D1 or c-Myc was demonstrated in any of the 12 normal ovarian specimens. (bmj.com)
  • Although our preliminary results need to be validated in a larger number of tumors, the abnormal expression of cyclin D1 and c-Myc in epithelial ovarian cancer reaffirms the notion that they are crucial components in the pathway of tumorigenesis and deserve further study. (bmj.com)
  • Epstein-Barr virus latent membrane protein expression and cyclin DI cell cyase protein expression in malignant and normal oesophageal tissues to see whether any variation in their expression in these tissues could be of diagnostic or prognostic value. (bvsalud.org)
  • EBV-LMPI protein expression and cyclin DI expression were studied immunohisto chemically in these tissue sections. (bvsalud.org)
  • However, proliferation of cardiomyocytes induced by nuclear-targeted cyclin D1 (D1NLS) stops after one or two rounds of cell cycles due in part to accumulation of p27Kip1, an inhibitor of cyclin-dependent kinase (CDK). (elsevierpure.com)
  • The new drug acts as an inhibitor of cyclin-dependent kinases 4 and 6, which are involved in promoting the growth of cancer cells, the FDA noted. (medscape.com)
  • The second cohort was required to have tumors that had an amplification of cyclin D1, loss of p16, or both. (medscape.com)
  • The delay of degradation of cyclin subunits is the cause of G1-phase prolongation under clinorotation leading to delay of pea seed germination. (cytgen.com)
  • Cyclin D1 and c-Myc are key participants in the cell-cycle pathway, in which aberrancies have been associated with malignant transformation. (bmj.com)
  • Thioredoxin regulates cell cycle via the ERK1/2-cyclin D1 pathway. (bvsalud.org)
  • It was then decided that patient selection based on cyclin D amplification or p16 loss was not likely to improve patient outcome. (medscape.com)
  • Molecular analysis of cyclin D1 modulators PRKN and FBX4 as candidate tumor suppressors in sporadic parathyroid adenomas. (cdc.gov)
  • Cyclins function as regulators of CDK kinases. (genetex.com)
  • Aims: Cyclins and other cell-cycle regulators have been used in several studies to regenerate cardiomyocytes in ischaemic heart failure. (elsevierpure.com)
  • IHC-P analysis of human tonsil tissue using GTX33611 Cyclin D1 antibody [RM241]. (genetex.com)
  • This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. (genetex.com)
  • WB analysis of HeLa cell lysate using GTX33611 Cyclin D1 antibody [RM241]. (genetex.com)
  • To investigate individual susceptibility to gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma, the authors studied the frequency of the common G870A polymorphism of CCND1, which encodes cyclin D1, a key cell cycle regulatory protein. (nih.gov)
  • A polymorphism (G870A) in exon 4 of the cyclin D1 (CCND1) gene creates an alternative splice site in its mRNA, encoding a protein with an altered C-terminal domain. (nih.gov)
  • 8. Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma. (nih.gov)
  • In this study, we show that overexpression of a regular component of the ERalpha transcription factor complex, cyclin D1, which occurs in approximately 40% of breast cancer patients, renders cells resistant to the new promising antiestrogen, arzoxifene. (nih.gov)
  • Overexpression of cyclin D1 alters the conformation of ERalpha in the presence of arzoxifene. (nih.gov)
  • No association was seen between genotype and cyclin D1 overexpression. (nih.gov)
  • Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms. (bvsalud.org)
  • Normal cell proliferation is closely regulated by proteins called cyclins. (ox.ac.uk)
  • Hyperglycemia for 4 days of chicken embryo incubation caused a reduction in cell proliferation in cardiac tissue due to suppression of the cell cycle, specifically the upregulation of P21 and downregulation of cyclin D1. (ohsu.edu)
  • Cell proliferation is tightly controlled by the cell-cycle regulatory proteins, primarily by cyclins and cyclin-dependent kinases (CDKs) in the G 1 phase. (molcells.org)
  • Cyclin D1 is required for proliferation of Olig2-expressing progenitor cells in the injured cerebral cortex. (unibas.ch)
  • Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. (nih.gov)
  • 18. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. (nih.gov)
  • Furthermore, ST water extract up-regulated expression of Cyclin D1 and CDK4 proteins. (bvsalud.org)
  • 11. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. (nih.gov)
  • 13. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. (nih.gov)
  • 6. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells. (nih.gov)
  • This effect is mediated by the upregulation of a CDK inhibitor p21, which causes the decrease in cyclin D1 and CDK4 protein levels and subsequent reduction of pRb hyperphosphorylation. (molcells.org)
  • Thus, the p21-cyclinD1/CDK4 signaling pathway plays a critical role in ARMS/Kidins220-dependent cell-cycle progression. (molcells.org)
  • 0.05) but did not correlate with cyclin D1 expression. (ox.ac.uk)
  • Objectives:This study was aimed to detect cyclin D1 in colorectal cancer patients and to correlate cyclin D1 expression with different pathological changes in colorectum.Methods: Tissues microarray paraffin block with 48 colorectal cancer samples were retrieved from the archives of Elrahma Medical Center. (sciencegate.app)
  • No correlation between cyclin D1 and D2 and growth rates or CD38 expression was observed. (medscape.com)
  • Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. (ox.ac.uk)
  • 16. OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia. (nih.gov)
  • The D cyclins were expressed differentially in chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), and mantle cell lymphoma (MCL) with strong staining of cyclin D1 and D2 in MCL, strong staining of cyclin D1 but weak staining of cyclin D2 in 4 of 5 PLLs, and low-level staining for both cyclins in most CLLs. (medscape.com)
  • 3. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. (nih.gov)
  • 10. Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. (nih.gov)
  • 12. Cyclin D1 splice variants. (nih.gov)
  • 14. Cyclin D1b splice variant promotes αvβ3-mediated adhesion and invasive migration of breast cancer cells. (nih.gov)
  • cyclin D1 not correlates with pathological alteration of colorectal cancer. (sciencegate.app)
  • In addition, there was a significantly higher progression rate for those patients with Ta/T1 disease whose tumours demonstrated cytoplasmic cyclin D1 staining. (ox.ac.uk)
  • Abstract Background: Cyclin D1 plays a vital role in cancer cell cycle progression and is overexpressed in many human cancers, including colorectal cancer. (sciencegate.app)
  • Immunohistochemistry was used to study cyclin D1 distribution in among patients in the case group. (nih.gov)
  • T2-T4 = 53) were stained for cyclin D1 using immunohistochemistry and a cyclin D1 index assigned. (ox.ac.uk)
  • 4. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. (nih.gov)
  • The results indicate that high-resolution flow cytometric evaluation of the D cyclins discriminates between the CD5+ B-cell lymphoproliferative disorders and might impart prognostic information in CLL. (medscape.com)
  • In a multivariate analysis, cyclin D1 expression is an independent prognostic indicator of survival in those patients with muscle-invasive disease. (ox.ac.uk)
  • 1. Expression Of Cyclin D1 Protein Isoforms And Its Prognostic Significance In Cervical Cancer. (nih.gov)
  • However, cyclin D1 levels were significantly higher in ZAP-70+ CLL cases, although no association between ZAP-70 and cyclin D2 was detected. (medscape.com)
  • These results indicate that cyclin D1 expression is significantly higher in low-stage, well differentiated bladder tumours and strongly correlates with waf1 expression. (ox.ac.uk)
  • Following siRNA knockdown of Raf-1, Western blot analysis revealed a significant decrease in Raf-1, cyclin D1, and all p-4EBP1 forms noted above. (nih.gov)
  • 2. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. (nih.gov)
  • 9. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. (nih.gov)
  • L'étude portait sur 20 patients atteints d'un carcinome gastrique, 20 patients souffrant d'une gastrite à H. pylori et 20 personnes en tant que groupe témoin. (who.int)
  • 15. Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b). (nih.gov)
  • The impact of Cyclin D1 on proliferating cells in the intact and injured mouse cortex. (unibas.ch)